

AD\_\_\_\_\_

Award Number: DAMD17-98-1-8550

TITLE: In Vivo Testing of Chemopreventive Agents Using the Dog  
Model of Spontaneous Prostate Carcinogenesis

PRINCIPAL INVESTIGATOR: David J. Waters, D.V.M., Ph.D.

CONTRACTING ORGANIZATION: Purdue Research Foundation  
West Lafayette, Indiana 47907-1021

REPORT DATE: October 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20041215 046

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> October 2003	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Sep 2002 - 1 Sep 2003)	
<b>4. TITLE AND SUBTITLE</b> In Vivo Testing of Chemopreventive Agents Using the Dog Model of Spontaneous Prostate Carcinogenesis			<b>5. FUNDING NUMBERS</b> DAMD17-98-1-8550	
<b>6. AUTHOR(S)</b> David J. Waters, D.V.M., Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Purdue Research Foundation West Lafayette, Indiana 47907-1021  E-Mail: waters@vet.purdue.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> The goal of this research was to demonstrate the feasibility of the dog model of spontaneous prostate carcinogenesis as a valuable model system to evaluate chemopreventive agents. From April 1, 2003 to March 31, 2004, we have further defined the anticancer effects of the trace mineral selenium on the aging prostate. Our work has generated the first evidence of a non-linear, U-shaped dose : response relationship between selenium status and DNA damage within the prostate. Importantly, the dose : response curve from elderly beagle dogs accurately predicts the relationship between selenium status and prostate cancer risk in men. In our Phase II proposal, we are focusing on interactions between selenium and the antiandrogen, finasteride. To accomplish this, we will conduct a 6 month intervention trial using elderly beagle dogs. At the time of this report, 57 dogs have undergone prostatic biopsy, randomized treatment assignment (no treatment, selenium alone, finasteride alone, or selenium plus finasteride), and necropsy after a 6 month intervention period. Interventions were well tolerated by all dogs. Biomarker analysis on tissues and body fluids collected pre-treatment, during the experimental period, and at time of euthanasia are currently in progress. Our experience indicates the dog model provides a useful model system to study the effects of cancer preventive agents on prostate cells in an appropriate context - in vivo within an aging prostate.				
<b>14. SUBJECT TERMS</b> Prostate cancer, chemoprevention, dog, selenium, finasteride, DNA damage, animal models				<b>15. NUMBER OF PAGES</b> 44
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4-8
Key Research Accomplishments.....	8
Reportable Outcomes.....	9-10
Conclusions.....	10
References.....	11
Appendices.....	12-44

## INTRODUCTION

Dogs and humans share a vulnerability for the spontaneous development of prostate cancer. Prevention rather than treatment may be the best approach to reduce the morbidity and mortality associated with prostate cancer. Our previous work documented the high prevalence of high-grade prostatic intraepithelial neoplasia in elderly pet dogs and its close association with invasive carcinoma. *In vivo* screening of promising chemopreventive agents using the dog model of spontaneous prostate carcinogenesis represents a novel approach to the prevention of prostate cancer. The goal of this Phase II Idea Development Award is to utilize the dog model to define further the anticancer effects of the trace mineral selenium. The scope of this work includes: (1) continued evaluation of data collected from our Phase I studies on dogs receiving daily supplementation with selenium; and (2) dog experiments testing the extent to which manipulation of the androgen milieu within the prostate (using the 5 $\alpha$  reductase inhibitor finasteride) significantly influences the response of the aging prostate to selenium supplementation. The long-term objective of this research is to utilize the dog as a pre-clinical model to test innovative ideas in cancer prevention and treatment, as well as to further understand the factors that regulate the response of the aging prostate to chemopreventive agents.



## BODY

### I. Continued Evaluation of Data Collected from Phase I Experiments

#### *What is the Relationship Between Selenium Status and the Level of Genotoxic Stress within the Aging Prostate?*

Using the dog model, we have explored the dose : response relationship between selenium status and DNA damage within the prostate. We studied 49 (8.5 – 10.5 year old) sexually intact male, retired breeder dogs that were randomly assigned to either a control group or to receive daily supplementation with selenomethionine or high selenium yeast at 3 or 6  $\mu\text{g/kg}$  body weight. After 7 months, toenail and prostate tissue specimens were collected immediately after euthanasia and analyzed for total selenium concentration using neutron activation analysis. Dogs from control and selenium treated groups were combined and subdivided into quartiles based on their toenail selenium concentration to evaluate the relationship between toenail selenium level. The extent of DNA damage within the prostate was measured by alkaline Comet assay. There is a non-linear, U-shaped relationship with a relatively narrow range of selenium that optimizes homeostasis within the prostate in terms of DNA damage reduction (**Figure 1A**). This U-shaped relationship between micronutrient status and biological response was predicted more than 20 years ago by Mertz [1] (**Figure 1B**). According to the Mertz model, a region of optimal nutrient status lies between two suboptimal (low and high) regions and the extreme values of deficiency and toxicity. Our data provide the first *in vivo* confirmation that Mertz's model is operational for an essential nutrient within the prostate. Importantly, this non-linear U-shaped relationship between selenium status and genotoxic stress within the prostate predicts that not all men will benefit from increasing their selenium status.





**Figure 1. A U-Shaped Dose-Response Curve Defines the Relationship Between Selenium and Genotoxic Stress in Prostate.** (A) U-shaped dose-response relationship between toenail selenium concentration and prostatic DNA damage in 49 elderly dogs that were physiologically equivalent to 65-year old men. (B) Model adapted from Mertz [1] predicting the biological response to an essential nutrient. The data from dogs provides the first *in vivo* confirmation that the Mertz model fits for selenium and procarcinogenic events within the prostate.

*Does the U-Shaped Relationship Between Toenail Selenium Concentration and Extent of Prostatic DNA Damage in Elderly Beagle Dogs Have Relevance to Selenium Status and Human Prostate Cancer Risk?*

Using data from the Health Professionals Follow-Up Study (HPFS), Yoshizawa et al. [2] found a strong inverse association between toenail selenium concentration and risk for advanced prostate cancer. Interestingly, multivariate analysis demonstrated an *apparent threshold effect*, with no additional prostate cancer protective effect at toenail concentrations exceeding 0.82 ppm. In another study, Brooks et al. [3] found a similar threshold effect.

We found that toenail concentrations in the lowest and highest quartiles of elderly beagle dogs in our study (mean of 0.50 ppm and 1.03 ppm, respectively) were quite similar to toenail concentrations seen in the HPFS (median of 0.66 ppm in lowest quintile; median of 1.14 ppm in highest quintile). *Fitting the human data from the HPFS to the dog curve produces an intriguing result – the same level of selenium status that minimizes prostatic DNA damage in dogs also minimizes prostate cancer risk in men.* In the HPFS, the highest risk for prostate cancer was in men in the lowest quintile of toenail selenium (median 0.66 ppm) – a value well outside the optimal range predicted by our model. Lowest prostate cancer risk was in men with a median value of 0.82 ppm, which falls within the optimal range of our model. *Thus, movement along our dog curve from low suboptimal to optimal selenium status (bold arrow in Figure 3) was associated with a 65% reduction in human prostate cancer risk.*

In addition, we analyzed data from the Nutritional Cancer Prevention trial of Clark et al. [4, 5], converting plasma selenium to an equivalent toenail selenium concentration.<sup>1</sup> Again, the dog curve correctly predicts that men in the lowest tertile of baseline selenium status (<0.71 ppm) would benefit from selenium supplementation. Men in the highest tertile in Clark's study had baseline selenium status (>0.81 ppm) already within the optimum range prior to selenium supplementation; these men did not benefit from selenium supplementation and their post-selenium supplementation selenium status was very high (median, 1.27 ppm).

Taken together, these findings provide strong rationale for using the aging dog prostate to mimic the aging human prostate to further understand the response of prostate cells to selenium. Our results support the hypothesis that toenails are a readily accessible surrogate tissue for monitoring the effects of dietary selenium supplementation on carcinogenic events within the aging prostate. The possibility of a threshold for the prostate cancer protective effects of selenium that can be assayed non-invasively warrants further investigation.

A manuscript reporting these results has been submitted for publication.

---

<sup>1</sup> We simultaneously measured toenail and plasma selenium concentration in 12 healthy human volunteers to generate a ratio ( $6.7 \pm 0.7$ ) to convert plasma selenium concentration to predicted toenail values. This technique appears valid because using our conversion, the average plasma selenium concentration in U.S. men (123 ng/ml) is equivalent to a concentration of 0.82 ppm in toenails, which is identical to the median selenium concentration measured in the toenails of men in the HPFS.

## II. Progress on Phase II Experiments

**TASK 1.** To determine if the effect of selenium/antiandrogen on biomarkers of carcinogenesis within the prostate (Months 1-36)

We have completed the 6 month intervention study in elderly sexually intact male dogs. After prostatic biopsy, 57 dogs have been randomized to 1 of 6 treatment groups: (1) no treatment; (2) selenium supplementation (3µg/kg SelenoExcell); (3) selenium plus low dose (0.25 mg/kg/day) finasteride; (4) selenium plus high dose (1mg/kg/day) finasteride; (5) low dose finasteride without selenium; and (6) high dose finasteride without selenium. After euthanasia, prostate tissues have been collected for biomarker analysis. Urine, serum, and toenails have also been collected for subsequent measurement of biomarkers.

Selenium and finasteride supplementation was well tolerated by all dogs. No technical problems have been encountered. A revised Statement of Work submitted in May 2003 was approved by Dr. Mishra that addresses some modifications in our laboratory analysis of tissues and body fluids. These include the measurement of total selenium rather than selenium metabolites, and additional assays to assess prostate cell sensitivity to apoptosis. A no-cost extension was approved in February 2004 to complete the project March 2005.

### *Does Selenium Supplementation Influence the Anti-trophic Effect of Finasteride on the Aging Prostate?*

As an initial step in analyzing our experimental results, we focused on the effects of treatment on prostate volume. For each dog, prostate size in 3 dimensions was measured with calipers prior to treatment and after 6 to 7 months treatment. Prostate weight was calculated using the formula: weight (g) = volume (cm<sup>3</sup>) x 0.602 + 1.16. The anti-trophic effect of finasteride on the prostate was assessed by calculating the percent change in prostate volume over the treatment period. Actual prostate weight recorded at the end of the study was strongly correlated with prostate weight calculated from prostate volume ( $r = 0.963$ ;  $p < 0.0001$ ), validating prostate volume as a robust and reliable index of prostate growth. Dogs in the control group had a median change in prostate volume of +15% over the treatment period. Similarly, dogs receiving supranutritional selenium supplementation had a 16% median increase in prostate volume. In contrast, finasteride-treated dogs had a 42% median reduction in prostate volume after 6 months of treatment ( $p < 0.0001$  vs. control group). Finasteride-treated dogs that received supranutritional selenium had a 38% median reduction in prostate volume, which did not differ from dogs treated with finasteride alone ( $p = 0.52$ ).

These preliminary data suggest that selenium status does not significantly influence the anti-trophic effects of finasteride on the aging prostate. The dog model enables us to study *in vivo* how differences in selenium status (i.e., nutritionally adequate versus supranutritional) influence prostate cell response to other potential cancer preventive agents. Further analysis of these dogs will determine to what extent the combination of selenium and finasteride affect biomarkers of growth regulation and carcinogenesis within the aging prostate.

### *Does Selenium Supplementation Alter the Androgen Milieu Within the Prostate?*

In this experiment, we also tested the hypothesis that selenium might exert its anticancer effects by significantly reducing intraprostatic concentrations of androgens. Using radioimmunoassay, we measured the concentration of testosterone and dihydrotestosterone (DHT) in snap-frozen prostate tissue samples obtained at necropsy from dogs after 6 months treatment. Compared to the control group, dogs that received daily selenium supplementation had a 39% reduction in mean intraprostatic testosterone concentration ( $p=0.05$ ). Similarly, mean DHT concentration within the prostates of selenium treated dogs was 14% lower than in control dogs, but this difference did not achieve statistical significance ( $p=0.25$ ). These preliminary data raise the intriguing possibility that reduction of intraprostatic androgens should be included as one of the potentially important pleiotropic effects of selenium on the prostate.

**TASK 2.** To determine the effect of 6 month treatment with selenium/antiandrogen on selenium homeostasis within the prostate and other tissues (Months 1-36)

Serum, toenails, prostate and other tissues have been collected from dogs. Upon completion of sample collection, all samples will be transported to the Morris Laboratory at University of Missouri where total selenium content will be assayed using neutron activation analysis.

### **KEY RESEARCH ACCOMPLISHMENTS**

- In elderly beagle dogs, there is a non-linear, U-shaped relationship between selenium status and accumulation of DNA damage within the prostate.
- The dose: response curve indicates a relatively narrow optimal range of selenium that maintains prostatic homeostasis, i.e. more selenium is not necessarily better.
- The optimal selenium status predicted by the dog model appears to have implications for human health, because men with the lowest risk of prostate cancer in the Health Professionals Follow-Up study had a median toenail selenium concentration of 0.82 ppm, a value that falls within the optimal range predicted by the dog model.
- The response of the aging prostate to the anti-trophic effects of the  $5\alpha$  reductase inhibitor finasteride is not significantly influenced by selenium status.
- Selenium treated dogs had lower concentrations of androgenic steroids in their prostate gland – daily selenium supplementation was associated with a 39% reduction in intraprostatic concentrations of testosterone and a 14% reduction in DHT.

## REPORTABLE OUTCOMES

### Manuscripts

Waters DJ, Chiang EC, Cooley DM, Morris JS. Making Sense of Sex and Supplements: Differences in the Anticarcinogenic Effects of Selenium in Men and Women. *Mut Res* (*in press* 2004).

### Published Scientific Abstracts

None

### Press Releases

Does Selenium Prevent Prostate Cancer? By Kathleen Wildasin. About.cancer.com, July 10, 2003.

Good News for Men (and Dogs) by Susan Edmiston. *Alternative Medicine*, October 2003, pp. 45-46.

Does Selenium Reduce the Risk of Developing Prostate Cancer? By Kathleen Wildasin, US TOO International Hot Sheet, October 2003.

### Patents

None

### Poster and Oral Presentations

#### *Invited Lectures at National and International Meetings*

Prostate Cancer Risk and DNA Damage: Translational Significance of Selenium Supplementation in a Canine Model. Keynote Speaker, University of Missouri Research Reactor (MURR) Science Day, Columbia, MO, May 2004

Relationship Between Selenium Status and the Extent of Genotoxic Stress within the Aging Prostate. International Conference on Antimutagenesis and Anticarcinogenesis, Pisa, ITALY, November 2003

#### *Posters presented at National and International Meetings*

Is the Anti-Trophic Effect of the 5 $\alpha$ -Reductase Inhibitor Finasteride on the Aging Prostate Influenced by Selenium Status? American Association for Cancer Research Frontiers of Cancer Prevention, Phoenix, AZ, October 2003

## Other

Based upon the significant research progress made by our group and others in better understanding the anticancer effects of the trace mineral selenium, Dr. Waters developed a graduate level course at Purdue University "Selenium in Health and Disease". The course focused on the relationship between selenium status and cancer risk, particularly the risk of prostate cancer. Discussions addressed the issues of measurement and epidemiology, mechanisms studied using *in vitro* and *in vivo* animal models, and interventional studies with human subjects. Students were enrolled in this 3 credit hour course for the first time in the Spring 2004 semester.

## CONCLUSIONS

During the next 10 years, the National Cancer Institute sponsored SELECT trial will study more than 32,000 men to evaluate whether selenium +/- vitamin E will decrease the incidence of human prostate cancer. However, the mechanisms by which selenium modulates key events in the multistep prostate carcinogenesis are unknown. Our work using the dog model yielded the first evidence that daily selenium supplementation can significantly decrease DNA damage within the aging prostate [6]. Furthermore, we showed for the first time that selenium can upregulate apoptosis of prostatic epithelial cells *in vivo* [6]. In our Phase II studies, we are further defining the mechanisms by which selenium supplementation exerts a prostate cancer protective effect. Our work to date takes an important step toward generating important and useful information necessary to develop selenium as a practical means of prostate cancer chemoprevention. Our research addresses a key underexplored area – the further development of an animal model system to study the effects of potential chemopreventive agents on cellular processes that regulate human prostate carcinogenesis. Our most recent findings provide new insight into the complex dose: response relationship between selenium status, genotoxic stress, and carcinogenesis within the aging prostate. Our experience indicates that the response of the human prostate to the anticarcinogenic effects of selenium can be correctly predicted using cost effective short-term studies in dogs, the non-human species most prone to prostate cancer development. This provides a novel approach that can be used to find the dose of cancer-fighting micronutrients that will optimize the design of future interventional trials in men to reduce prostate cancer mortality. The recent evaluation of finasteride in a large prostate cancer prevention trial in 18,000 men has sparked an intense interest in the potential anticancer effects of antiandrogens within the prostate. Completion of our Phase II experiments will provide valuable insights into the consequences of manipulating selenium and androgen status on biomarkers of prostatic carcinogenesis.

## REFERENCES

1. Mertz W. The essential trace elements, *Science*, 1981, 213: 1332-1338.
2. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. *J Natl Cancer Inst* 1998;90:1219-24.
3. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. Plasma selenium level before diagnosis and the risk of prostate cancer development. *J Urol* 2001; 166:2034-8.
4. Clark LC, Combs GF, Jr, Turnbull BW, Slate E, Alberts D, Abele D, Allison R, Bradshaw J, Chalker D, Chow J, Curtis D, Dalen J, Davis L, Deal R, Dellasega M, Glover R, Graham G, Gross E, Hendrix J, Herlong J, Knight F, Krongrad A, Leshner J, Moore J, Park K, Rice J, Rogers A, Sanders B, Schurman B, Smith C, Smith E, Taylor J, Woodward J. The nutritional prevention of cancer with selenium 1983-1993: a randomized clinical trial. *J Am Med Assoc* 1996;276:1957-1963.
5. Clark LC, Dalkin B, Krongrad A, Combs GF, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *Br J Urol* 1998; 81: 730-4.
6. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF Jr, Glickman LT, Oteham C, Schlittler DL, Morris JS. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. *J Natl Cancer Inst* 2003; 95:237-41.

## APPENDIX

### Manuscripts

Waters DJ, Chiang EC, Cooley DM, Morris JS. Making Sense of Sex and Supplements: Differences in the Anticarcinogenic Effects of Selenium in Men and Women. *Mut Res* (in press 2004).

### Press Releases

Does Selenium Prevent Prostate Cancer? by Kathleen Wildasin. *About.cancer.com*, July 10, 2003.

Good News for Men (and Dogs) by Susan Edmiston. *Alternative Medicine*, October 2003, pp. 45-46.

Does Selenium Reduce the Risk of Developing Prostate Cancer? by Kathleen Wildasin, *US TOO International Hot Sheet*, October 2003.

### Scientific Abstracts

Waters DJ. Prostate Cancer Risk and DNA Damage: Translational Significance of Selenium Supplementation in a Canine Model. University of Missouri Research Reactor (MURR) Science Day, Columbia, MO, May 2004

Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Glickman LT, Morris JS. Relationship Between Selenium Status and the Extent of Genotoxic Stress within the Aging Prostate. International Conference on Antimutagenesis and Anticarcinogenesis, Pisa, ITALY, November 2003

Cooley DM, Shen S, Oteham C, Schlittler D, Glickman LT, Bostwick DG, Morris JS, Combs Jr GF, Waters DJ. Is the Anti-Trophic Effect of the 5 $\alpha$ -Reductase Inhibitor Finasteride on the Aging Prostate Influenced by Selenium Status? American Association for Cancer Research Frontiers of Cancer Prevention, Phoenix, AZ, October 2003





Review

# Making sense of sex and supplements: differences in the anticarcinogenic effects of selenium in men and women

David J. Waters<sup>a,b,\*</sup>, Emily C. Chiang<sup>b</sup>, Dawn M. Cooley<sup>a,b</sup>, J. Steven Morris<sup>c</sup>

<sup>a</sup> Gerald P. Murphy Cancer Foundation, Seattle, WA, USA

<sup>b</sup> Department of Veterinary Clinical Sciences, Purdue University, 1291 Cumberland Ave, 1248 Lynn Hall, West Lafayette, IN 47907, USA

<sup>c</sup> University of Missouri-Columbia Research Reactor Center, Columbia, MO, USA

Received 15 December 2003; received in revised form 9 February 2004; accepted 12 February 2004

## Abstract

The role of the essential trace mineral selenium in human health and disease is currently a subject of intense interest. In particular, the possible cancer preventive effects of dietary selenium supplementation are now being investigated in several large, randomized trials. The association between selenium status, genotoxic damage, and cancer risk remains enigmatic because epidemiologic studies have failed to consistently link low selenium status with increased cancer risk in men and women. In this paper, we considered the evidence that there are sex-based differences in the anticarcinogenic effects of selenium in humans. We focused our review on prospective human studies in which the relationship between selenium status and cancer risk in men and women was directly compared. Results from cohort studies conducted in seven countries (Belgium, China, Finland, Japan, Netherlands, Norway, and United States) were used to assess the strength of association between low selenium status and the incidence of all cancers, sex-specific cancers, and cancers at particular anatomic sites. In general, the available data support the hypothesis that cancer risk in men is more profoundly influenced by selenium status than cancer risk in women. Factors contributing to the apparent difference in the effects of selenium on cancer incidence in men and women may include sex-based differences in the metabolism and/or tissue distribution of selenium, as well as sex- or gender-related factors that influence tumor biology. Studies are needed to further define the dose-response relationship between selenium and cancer risk in men and women. A more complete understanding of the mechanisms by which selenium modulates cancer initiation and progression is needed to optimize dietary selenium supplementation as a practical cancer preventive strategy. Ultimately, achieving the ambitious goal of cancer prevention may require sex- and gender-specific approaches.

© 2004 Published by Elsevier B.V.

**Keywords:** Cancer incidence; Epidemiology; Cancer prevention; Dietary supplements; Micronutrients; Gender-specific risk; Cohort studies; Sex-based differences

## 1. Introduction

The trace mineral selenium is an essential component of several metabolically important enzymes, including the antioxidant glutathione peroxidases and thioredoxin reductases [1–3]. Because dietary selenium supplementation inhibits cancer development in

\* Corresponding author. Tel.: +1 765 494 9271;

fax: +1 765 775 1006.

E-mail address: [dwaters@gpmcf.org](mailto:dwaters@gpmcf.org) (D.J. Waters).

a variety of experimental animal models [4–6], there is growing interest in the prospect that selenium status significantly influences human cancer risk.

To date, the epidemiologic evidence from prospective human studies is inconsistent—some investigations show an increased risk of cancer in individuals with lowest selenium status, whereas other studies report null results [7,8]. In a randomized, placebo-controlled study of older Americans, daily use of an oral selenium supplement substantially reduced the risk of several cancers, most notably cancer of the prostate [9]. These results suggested the exciting possibility that significant reductions in cancer risk may be realized with low, non-toxic doses of selenium that could readily be achieved by dietary supplementation. The cancer protective effects of selenium may be mediated by selenoproteins operating within enzymatic systems which are saturated at relatively low levels of selenium, or by selenium metabolites that increase substantially under conditions of supranutritional selenium intake [10].

In 1987, Kok et al. [11] in the Netherlands reported that low selenium status was associated with increased cancer risk in men, but not in women. They proposed that serum selenium may only be a useful predictor for cancer risk in men. This hypothesized sex-based difference was consistent with earlier data reported from Finland [12] and the United States [13].

In this article, we consider the evidence that there are sex-based differences<sup>1</sup> in the anticarcinogenic effects of selenium in humans. To accomplish this, we critically review data from prospective human studies in which the association between selenium status and subsequent cancer risk in men and women was directly compared. We also review prospective studies that were restricted to males or females as well as studies with both men and women in which sex-specific cancer risk was not reported; our discussion of these studies is limited. The purpose of this review is to provide a conceptual framework for future investiga-

tions on the underlying mechanisms and public health implications of the apparent sex-based differences in selenium anticarcinogenesis.

## 2. Sex-based differences in the association between selenium status and total cancer incidence

Prospective cohort studies provide an opportunity to evaluate the association between nutrient status and the subsequent risk for cancer. In these studies, pre-diagnostic biological samples are collected from a cohort of healthy individuals who are free of cancer. After the cohort is followed longitudinally over time, samples are analyzed from all cancer cases and a matched group of controls who did not develop cancer during the observational period.

Table 1 summarizes data from six prospective cohort studies [11–13,16–18] conducted in five countries (Finland, Japan, Netherlands, Norway, and United States) in which the effect of dietary selenium intake on total cancer incidence in men and women was measured by comparing the serum selenium concentration of cancer cases versus controls without cancer. Among men, cancer cases had significantly lower selenium concentration than controls ( $P < 0.05$ ) in four of six studies. On average, males that subsequently developed cancer at any site had an 8% (range, 5–23%) lower selenium concentration than men who did not develop cancer. In contrast, there was no significant difference between selenium concentration in female cases versus controls in any of the studies. Women with cancer had higher selenium concentration than men with cancer in four of the studies. This is consistent with the findings of Criqui et al. [19] in which mean serum selenium concentration in 74 men that subsequently had cancer mortality was 4  $\mu\text{g/L}$  lower than controls ( $P < 0.40$ ); in contrast, 62 women with cancer mortality had serum selenium concentration 11  $\mu\text{g/L}$  higher than controls ( $P = 0.03$ ).

In three studies [11,16,20], the relative risk of cancer in individuals with the lowest serum selenium was compared with the incidence of cancer in individuals with the highest selenium status. In Belgium, Finland, and the Netherlands, men with low selenium status had a significantly higher relative risk (2.2–2.7-fold increase) of cancer at all sites than men with high selenium. In contrast, women with low serum selenium

<sup>1</sup> In this article, we use the terms sex and gender to discuss the differences between men and women. These terms are used in accordance with definitions proposed by the 2001 Institute of Medicine Report, "Exploring the Biological Contributions to Human Health: Does Sex Matter?" [14]. The term sex is used when differences are primarily biological in origin and may be genetic or phenotypic; gender is used when referring to social and cultural influences based on sex [15].

Table 1  
Mean pre-diagnostic serum selenium concentration in cancer cases and matched controls from six prospective cohort studies

Cohort	Cases	Mean $\pm$ S.D. serum selenium concentration ( $\mu\text{g/L}$ )		P-value
		Case	Control	
Finland				
Salonen et al. [12]	16 male smokers	49.3	63.5	<0.05
	14 male non-smokers	49.9	58.4	>0.05
	21 female (all non-smokers)	59.5	60.5	>0.05
Knekt et al. [16]	597 male	59.1 $\pm$ 17.5	62.5 $\pm$ 15.4	<0.001
	499 female	63.6 $\pm$ 17.4	63.9 $\pm$ 14.3	>0.05
Japan				
Ujiie and Kikuchi [18]	35 male	105.2	112.8	0.18
	38 female	97.4	102.7	0.25
Netherlands				
Kok et al. [11]	40 male	116.7 $\pm$ 4.0	126.4 $\pm$ 3.1	0.04
	29 female	130.6 $\pm$ 6.0	129.3 $\pm$ 4.3	0.83
Norway				
Ringstad et al. [17]	26 male	124.0	130.3	0.08
	34 female	123.2	127.9	0.36
USA				
Willett et al. [13]	60 male	127.0	137.0	0.008
	51 female	132.0	134.0	0.57

had a relative risk to develop cancer that did not differ significantly from unity (Fig. 1).

Garland et al. [21] analyzed the association between selenium and cancer risk in women (503 cancer cases and matched controls) in the Nurses Health Study. Toenail selenium concentration was not inversely associated with overall cancer risk or cancer risk at any site. The authors concluded that higher selenium intake within the range typical for US women was not protective against cancer development in women.


Taken together, these studies suggest that overall cancer incidence in men is more profoundly affected by low selenium status than is cancer incidence in women.

### 3. The association between selenium status and risk of breast cancer and prostate cancer

To further analyze the influence of sex or gender-related factors on the anticarcinogenic effects of selenium, we explored the association between selenium status and risk of two sex-specific cancers—

breast cancer and prostate cancer. Fig. 2 summarizes data collected from the largest prospective cohort studies conducted in Finland, Netherlands, and United States. An inverse association between serum selenium concentration and prostate cancer risk was not seen in the Finnish study ( $n = 61$  cases) [16]. However, two large studies from the Netherlands ( $n = 540$  cases) and United States ( $n = 181$  cases) showed that men with low selenium status had a significantly increased risk ( $\text{RR} = 1.5$  and  $2.9$ , respectively) of prostate cancer compared to men with high selenium status [22,23].

In a secondary cohort analysis of the Alpha-Tocopherol Beta Carotene (ATBC) Cancer Prevention Study, no significant association between low selenium intake and prostate cancer risk was found in the placebo treated or  $\alpha$ -tocopherol treated groups [24]. Similarly, low baseline selenium status was not a significant risk factor for subsequent prostate cancer in the Carotene and Retinol Efficacy Trial (CARET) [25]. Among Japanese American men in Hawaii, low selenium status was associated with a significant increased risk of prostate cancer in current smokers [ $\text{RR} = 5.0$  (1.3–10.0)] and past smokers [ $\text{RR} = 2.0$



<sup>†</sup> Represents the relative cancer risk for individuals with low selenium status compared to cancer risk in individuals with high selenium status. For each sex, cancer risk in individuals with high selenium status equals 1.0.


Fig. 1. Relative risk of cancer (all sites) associated with low selenium status in men and women from three prospective cohort studies.

(0.9–5.0)], but not in never smokers [RR = 1.25 (0.5–2.5)] [26]. There was a non-significant trend toward increased prostate cancer risk with low selenium in a Washington County, MD cohort study [27]. More recently, low selenium status was associated with a four-fold increase in prostate cancer risk among participants of the Baltimore Longitudinal Study on Aging [28].

In contrast to prostate cancer, cohort studies lend little support for the hypothesis that low selenium status confers an increased risk of breast cancer [29–34]. Two large studies from the Netherlands ( $n = 202$  cases; RR = 1.1) and United States ( $n = 434$  cases; RR = 0.9) showed a null association between breast cancer risk and selenium status [33,34].

#### 4. Sex-based differences in the association between selenium status and risk of particular cancer types

Next, we sought to determine whether there were sex-based differences in the association between selenium status and cancer incidence at particular anatomic sites. Figs. 3–5 summarize the data from prospective studies in which the risk of specific cancers in men and women was compared. Data from Finland (lung, colorectal, stomach, pancreatic, urinary tract, and non-melanoma skin cancer), Netherlands (lung, colorectal, and stomach cancer), and United States (lung, pancreatic cancer) are summarized below for each cancer site. With two exceptions [30,35],



<sup>†</sup> Represents the relative cancer risk for individuals with low selenium status compared to cancer risk in individuals with high selenium status. For each sex, cancer risk in individuals with high selenium status equals 1.0.

Fig. 2. Relative risk of prostate cancer and breast cancer associated with low selenium status in 11 prospective cohort studies.


the cutoffs used to define low versus high selenium status in these cohorts are shown in Fig. 6. Table 2 shows the factors used in these prospective studies to match cases with controls and to conduct multivariate analysis of cancer risk versus selenium status.

#### 4.1. Lung cancer

The risk of lung cancer in Finnish men was 3.3 times greater in men with low selenium status than in those

with high selenium status ( $P$  for trend  $<0.001$ ) [16] (Fig. 3). In that study, there were only nine evaluable cases of lung cancer in women, and therefore no valid conclusions could be posited regarding the association between selenium status and female lung cancer risk.

In a Netherlands cohort study [36], men with low selenium status had a statistically significant two-fold increased risk of lung cancer. Women with low selenium had a 2.5-fold increased risk of lung cancer compared to women with high selenium status, but this




<sup>†</sup> Represents the relative cancer risk for individuals with low selenium status compared to cancer risk in individuals with high selenium status. For each sex, cancer risk in individuals with high selenium status equals 1.0.

Fig. 3. Relative risk of lung and colorectal cancer associated with low selenium status in men and women from prospective cohort studies.

211 did not reach statistical significance perhaps due to the  
212 relatively small number of female cases ( $n = 32$ ).


213 Men and women with low selenium status had similar  
214 increases in risk of lung cancer in a Washington  
215 County, MD cohort study (CLUE II) [35]. Low baseline  
216 selenium status was not a significant risk factor  
217 for lung cancer in men or women in the Carotene and  
218 Retinol Efficacy Trial [25].

219 It is notable that women with lung cancer in the  
220 Nurses Health Study had significantly lower toenail  
221 selenium concentration than matched controls  
222 ( $P = 0.03$ ) [21]. However, selenium status had no  
223 significant influence on lung cancer risk in women  
224 after adjusting for smoking status [RR and 95% CI  
225 in the lowest versus highest tertile = 0.23 (0.03–  
226 1.85)].



† Represents the relative cancer risk for individuals with low selenium status compared to cancer risk in individuals with high selenium status. For each sex, cancer risk in individuals with high selenium status equals 1.0.

Fig. 4. Relative risk of stomach and pancreas cancer associated with low selenium status in men and women from prospective cohort studies.



† Represents the relative cancer risk for individuals with low selenium status compared to cancer risk in individuals with high selenium status. For each sex, cancer risk in individuals with high selenium status equals 1.0.

Fig. 5. Relative risk of urinary tract and non-melanoma skin cancer associated with low selenium status in men and women from prospective cohort studies.

## 227 4.2. Colorectal cancer

228 The association between colorectal cancer risk and  
 229 selenium status was not profoundly different in men  
 230 and women in two evaluable studies [16,37] (Fig. 3).  
 231 Rectal cancer risk was *lowest* in Dutch women with  
 232 low selenium status, but this did not reach statistical  
 233 significance [36].

## 4.3. Stomach cancer

234

235 Data from two evaluable studies showed that risk  
 236 of stomach cancer in men with low selenium status  
 237 was significantly increased (RR = 2.5 Netherlands;  
 238 RR = 11.1 Finland) [16,37] (Fig. 4). In contrast, low  
 239 selenium status in women did not confer an increased  
 risk of stomach cancer. In fact, the relative risk of





Fig. 6. Cutoffs used to define low vs. high selenium groups<sup>†</sup> within study cohorts from Finland, China, Belgium, Netherlands, and United States.





<sup>†</sup>Arrows represent the selenium concentration cutoffs for the low and high selenium groups that were used to estimate the relative risk of cancer associated with low selenium status. Relative risks are shown in Figures 1-5.

<sup>††</sup>For the purpose of comparing studies in which selenium status was measured by either serum or toenail selenium levels, the serum selenium concentration reported in these six studies are expressed as toenail selenium equivalents here. The toenail and plasma selenium concentration in 12 healthy human volunteers were simultaneously measured to generate a ratio ( $6.7 \pm 0.7$ ) that could be used to convert plasma selenium concentration to predicted toenail values [J.S. Morris, unpublished data]. In this figure, toenail selenium equivalents (ppm) = serum selenium concentration ( $\mu\text{g/L}$ )  $\times$  0.0067.

Fig. 6. (Continued).

240 stomach cancer was *lower* in Dutch women with low  
241 selenium compared to those with high selenium status  
242 [37].

#### 243 4.4. Pancreatic cancer

244 Data from both Finland [16] and the United States  
245 [38] showed statistically significant sex-based differ-

ences in the association between selenium status and  
risk of pancreatic cancer (Fig. 4).

#### 248 4.5. Urinary tract cancer

249 The relationship between selenium and risk of uri-  
250 nary tract cancer in Finnish men and women sup-  
251 ported the hypothesis that there are sex-based dif-

Table 2

Factors used in prospective studies for matching cases with controls and for multivariate analysis of cancer risk vs. selenium status

Cohort	Factors				Other
	Sex	Age	Smoking status	Sample collection	
Belgium					
Kornitzer et al. [20]	✓	✓			Body mass index; intake of alcohol, total energy, total fat, saturated fat, dietary fiber, retinol, and Vitamin C
China					
Mark et al. [42]	✓	✓			
Finland					
Salonen et al. [12]	✓	✓	✓		
Knekt et al. [16]	✓	✓	✓		Residence
Japan					
Ujiie and Kikuchi [18]	✓	✓			Residence
Netherlands					
Kok et al. [11]	✓	✓	✓		
van Noord et al. [30]	✓	✓		✓	Residence, premenopausal status
van den Brandt et al. [22,33,36,37]	✓	✓	✓	✓	Education level; intake of alcohol and energy [33], beta-carotene and Vitamin C [37]
Norway					
Ringstad et al. [17]	✓	✓	✓	✓	Residence
USA					
Willett et al. [13]	✓	✓	✓	✓	Initial blood pressure, antihypertensive medication, randomization, parity and menopausal status (women)
Burney et al. [38]	✓			✓	Race
Hunter et al. [34]	✓	✓		✓	Intake of alcohol
Garland et al. [21]	✓	✓	✓		Toenail weight, laboratory batch
Comstock et al. [35]	✓	✓	✓	✓	
Yoshizawa et al. [23]	✓	✓	✓	✓	Body mass index, residence; intake of lycopene, saturated fat and calcium
Dorgan et al. [29]	✓	✓	✓	✓	Body mass index, time of diagnosis, total serum cholesterol
Nomura et al. [26]	✓	✓	✓	✓	Subgroups
Helzlsouer et al. [27]	✓	✓	✓	✓	Race
Brooks et al. [28]	✓	✓	✓	✓	Body mass index, intake of alcohol
Goodman et al. [25]	✓	✓	✓	✓	Year of randomization, intervention arm, exposure population

ferences in the anticarcinogenic effects of selenium [16] (Fig. 5). Males with low serum selenium had a non-significant *increased* relative risk of 1.2 compared to males with high selenium status. However, females with low serum selenium had an 80% *decreased* urinary tract cancer risk ( $P = 0.06$ ) compared to females with high selenium status.

#### 4.6. Non-melanoma skin cancer

Men in the Finnish cohort [16] who had the lowest serum selenium had a non-significant two-fold *increased* skin cancer risk. In contrast, females with low serum selenium had a non-significant 40% *decreased* risk of skin cancer (Fig. 5).

## 5. Results of the Nutritional Cancer Prevention Trial

In 1983, Clark et al. [9] launched the Nutritional Cancer Prevention Trial (NCPT) to determine whether daily selenium supplementation with selenium would significantly decrease the incidence of cancer in patients with non-melanoma skin cancer. In the NCPT, 1312 participants (980 men, 332 women) were randomized to treatment groups that received placebo or 200  $\mu\text{g}$  selenium daily in the form of high selenium yeast.<sup>2</sup> When data from the entire blinded treatment period were analyzed [39], men receiving selenium supplementation had a 33% reduction in overall cancer incidence [hazard ratio (95% CI) = 0.67 (0.50–0.89;  $P = 0.005$ ]. In contrast, women who received supplementation had a non-significant *increase* in total cancer incidence [hazard ratio = 1.20 (0.66–2.20;  $P = 0.55$ ]. The apparent cancer protective effect of selenium supplementation was limited to males, even after adjusting for age and smoking status. Selenium supplementation was associated with a 26% reduction in risk of lung cancer and a 54% reduction in risk of colorectal cancer, but these results were not statistically significant after a mean of 7.4 years follow-up. However, the significant reduction in prostate cancer that was originally reported remained highly significant (52% reduction;  $P = 0.005$ ) [40]. Low baseline selenium status prior to supplementation was an important predictor of the prostate cancer protective effects of dietary selenium supplementation [39,40]. It is interesting to note that selenium supplementation was associated with a non-significant *increase* in the incidence of five cancer types: melanoma, bladder, breast, head and neck, and lymphoma/leukemia [39].

Taken together, the results of this interventional trial support the hypothesis that overall cancer incidence in men may be more responsive to changes in selenium status than in women. However, a balanced interpretation of the NCPT results must consider that neither overall cancer mortality nor site-specific cancer incidence (with the exception of non-melanoma skin cancer) were primary endpoints of the study. Moreover, this trial was not adequately powered to detect a can-

cer protective effect in women because 75% of the participants were men.

## 6. Results of the General Population Trial (Linxian, China)

From 1986 to 1991, the General Population Trial was conducted in Linxian, China to determine if nutritional supplementation could significantly reduce cancer incidence, cancer mortality, or overall mortality [41]. Twenty-nine thousand five hundred and eighty-four adults were randomized to receive placebo or one of seven different combinations of nutrient supplements. Compared with the placebo group, a significant 13% reduction in overall cancer mortality was observed in the group receiving Factor D, a supplement containing selenium (50  $\mu\text{g}$ ) in the form of selenized yeast,  $\beta$ -carotene (15 mg), and  $\alpha$ -tocopherol (30 mg). However, no information was provided on whether men and women receiving this selenium-containing supplement experienced equivalent cancer protective effects.

Recently, Mark et al. [42] analyzed the relationship between pre-trial (baseline) serum selenium concentration and subsequent risk of developing esophageal and gastric cancer in the participants of the General Population Trial. Low baseline selenium status was associated with a significant increase in risk of esophageal cancer [RR = 1.8 (1.4–2.3)] and cancer of the gastric cardia [RR = 2.1 (1.5–3.0)], but not cancers affecting the non-cardiac region of the stomach [RR = 0.9 (0.5–1.8)]. Relative risk estimates for cancers at these three sites were nearly identical in men and women. Interestingly, among individuals with low baseline selenium status, the high risk of esophageal and gastric cardia cancers was not significantly influenced by selenium treatment, i.e. the development of incident cancers was similar in the selenium supplemented and non-supplemented groups. Apparently, the high risk of cancer associated with low selenium status could not be reduced by daily supplementation with 50  $\mu\text{g}$  of selenium.<sup>3</sup>

<sup>2</sup> High selenium yeast contains a cocktail of different organic selenium compounds; selenomethionine is the most abundant form (~85%) of selenium in this supplement.

<sup>3</sup> This level of supplementation resulted in a more than two-fold increase in total daily selenium intake because the estimated selenium intake in residents of Linxian was 36–42  $\mu\text{g}$  selenium/day [43].

The results of the General Population Trial do not support the hypothesis that there are differences between men and women in the association between low selenium status and subsequent cancer risk. However, the epidemic rate of esophageal and gastric cancer (these sites accounted for 87% of all cancer deaths) and consistently low concentration of several micronutrients in the inhabitants of Linxian make it difficult to generalize these findings to Western populations [44].

## 7. Other studies

To determine whether the overarching hypothesis—that low selenium status has a stronger association with cancer risk in men than in women—was refuted by other prospective studies, we also reviewed studies that were restricted to males or females as well as those that included both men and women in which analysis of sex-specific cancer risk was not reported. These included 24 reports relating pre-diagnostic selenium concentration in blood or toenails to subsequent cancer incidence at the following anatomic sites: stomach, colon, rectum, or gastrointestinal; lung or respiratory; lymphoma, leukemia, or hematologic; urinary bladder and other urogenital; skin (squamous cell or basal cell carcinoma, melanoma); oropharyngeal; hepatocellular carcinoma; cervical and ovarian; all sites [19,45–66]. Nine of these studies had exclusively or predominately males [45–53] and three studies had exclusively females [54–56]. In the remaining studies, sex-based analysis was not reported [57–64] or was incomplete [19,65–67].

Although the results of these studies varied, none persuasively argued against the hypothesis. However, conclusions based upon a survey of the literature may overestimate real differences in the relationship between selenium and cancer risk in men and women. There may have been no significant differences in the association between selenium status and cancer risk in men and women in studies in which results of sex-based analysis were not reported. We also recognize that there is inherent bias which favors publication of significant rather than non-significant results.

## 8. Potential underlying explanations for the apparent sex-based differences in the anticarcinogenic effects of selenium

### 8.1. Sex-specific cancers affecting men and women may differ in their response to selenium

Differences in the association between selenium status and total cancer incidence in men and women may reflect that certain sex-specific cancers of men (e.g. prostate cancer) are selenium responsive, whereas those affecting women (e.g. breast cancer) are insensitive to changes in selenium status. However, Garland et al. [21] showed a null association between selenium status and the incidence of 503 non-breast cancers in women of the Nurses Health Study. This suggests that breast cancer cannot solely account for the weak association observed between selenium status and overall cancer incidence in women.

### 8.2. Sex-based differences in tumor biology

Growing evidence suggests there are sex-based differences in the biology of particular types of cancer that affect both men and women [68]. For example, the frequency of G to T transversions in the p53 tumor suppressor gene are higher in the lung cancers of female smokers than in male smokers [69]. After adjusting for smoking exposure, non-tumorous lung tissue of women had higher levels of DNA adducts than lung tissue from men [70]. It has been speculated that some of the sex-based differences in tumor biology might reflect a diminished DNA repair capacity in women [71]. It is plausible that sex-based differences in selenium's effects on cancer incidence are the consequence of differences in certain tumor cell or host factors that favor cancer progression in men and women. A more complete understanding of the molecular and cellular biological differences between the cancers of men and women could help to elucidate the specific mechanisms by which selenium exerts its anticancer effects [15].

### 8.3. Sex-based differences in the dose-response relationship between selenium and cancer prevention

The dose-response for the anticarcinogenic effect of selenium may be significantly modified by sex or

gender-related factors. If this hypothesis is correct, the level of selenium that minimizes cancer risk would be different in men and women. Indeed, in some studies [16,37], women with the lowest selenium levels had the *lowest* risk for colorectal, stomach, urinary tract, and non-melanoma skin cancers. Analysis of data collected from four Canadian provinces suggested that men and women have non-linear dose-response relationships that are not superimposable [72]. In the Canadian study, the slope of the regression between estimated age-adjusted cancer death rates (all sites) and toenail selenium concentration was steeper for males, indicating that estimated cancer mortality in men was more strongly influenced by incremental changes in selenium status [72]. Sizeable international differences in selenium status (i.e. toenail selenium levels in the low selenium status group within cohorts from Finland, Netherlands, and United States were <0.33, <0.50, and <0.91 ppm, respectively; Fig. 6) provide an opportunity to determine whether selenium's influence on cancer incidence is strengthened or abrogated within populations that have relatively low selenium intake.

#### 8.4. Sex-based differences in metabolism or tissue distribution of selenium

From animal studies, it is apparent that there are sex-based differences in the metabolism and tissue concentrations of selenium [73]. The vulnerability of dogs and rodents to the toxicity of selenium compounds is influenced by sex; males were more sensitive than females to the toxic effects of intragastric or oral doses of L-selenomethionine [74]. Interestingly, in some rat studies, sex-based differences in toxicity were observed despite equivalent plasma concentrations in males and females [74].

Population-based studies reveal differences in the toenail selenium concentration of men and women, suggesting that the biodistribution of dietary selenium in humans is influenced by sex-based factors. Mean toenail selenium level in men was lower than in women in the Netherlands [75], Canada [72], and United States [76]. It is unclear whether high concentrations of selenium harbored within "priority tissues" of the male reproductive tract contribute to the lower toenail selenium concentrations seen in men. It is unlikely that the sex-based differences in selenium

status can be explained by higher dietary selenium intake in women. Whole body residence time of selenium has been estimated by Patterson et al. [77] to be greater in men than in women. Also, urinary excretion of selenium per kilogram of body weight in females may be higher than in males [78]. However, in contradiction to the aforementioned studies, analysis of 7102 male and 7517 female participants in NHANES III showed that mean serum selenium concentration was slightly higher in men (men = 124 µg/L versus women = 122 µg/L;  $P < 0.0001$ ) [79].

Although unproven, men and women may differ in the rate of formation or tissue distribution of certain anticarcinogenic metabolites [6] of selenium. This raises an important methodologic issue because measurement of total selenium concentration within nails or blood may be an insensitive means of detecting individual differences in the concentration of cancer fighting selenium metabolites.

#### 8.5. Sex-based differences in the interaction between selenium and other factors

There may be differences between men and women in the extent to which selenium status is influenced by confounding variables, such as health-related behaviors or dietary intake of other nutrients. For example, alcohol consumption was positively associated with serum selenium in women, but not in the men of NHANES III [79]. Also, the inverse association between toenail selenium concentration and smoking was reported to be stronger in men than in women [75].

### 9. Knowledge gaps and summary

In a recent review of the epidemiology of selenium and human cancer, Vinceti et al. [7] stated that "the relationship between the trace element selenium and the etiology of human cancer in humans remains elusive and intriguing". In order to understand the role that selenium plays in cancer protection, the biological factors and methodological issues contributing to the inconsistency of the epidemiological evidence linking low selenium status and increased cancer risk must be identified. In this survey, we evaluated the

strength of evidence supporting the hypothesis that there are sex-based differences in the anticarcinogenic effects of selenium. We conclude that, in general, the data support the hypothesis that cancer risk in men is more profoundly influenced by selenium status than in women. However, our analysis revealed relatively few informative prospective studies that directly compared the association between selenium and cancer risk in men and women. This was particularly true for men and women living in the United States. The most consistent sex-based difference within Western populations was the association between low selenium status and cancer incidence at all sites, and in particular, the cancers of the stomach and pancreas. Data supporting a difference in men and women was weakest for colorectal cancer. The influence of sex on the anticancer effects of selenium has not been extensively evaluated in animal tumor models. Relevant hypotheses could be formally tested using the most appropriate animal models and selenium doses relevant to human populations [80].

In several published studies [57–64], the results from sex-specific analysis of cancer incidence were not reported. Future studies should report the results of these analyses, even if no differences between men and women are found. All analyses should appropriately consider potential confounding variables, such as age and smoking status. Clearly, a more complete understanding of the extent to which sex modifies the influence of nutritional status (and other factors) on cancer risk is needed to establish sound health recommendations.

Finally, the anticarcinogenic dose–response of most cancer-fighting nutrients is unknown. It is doubtful that observational data from cohort studies can reliably predict the cancer risk reduction achievable with high doses of nutrient supplements, because the expected nutrient levels in supplement users are likely to exceed the range seen in the general population [25]. As scientists and clinicians seek to identify the dietary intake of selenium that minimizes cancer risk, it will be important to determine whether the dose–response relationship between selenium and anticarcinogenesis is non-linear [81,82]. A non-linear dose–response predicts that not all persons will benefit from increasing their selenium intake through daily supplementation. The possibility that the anticarcinogenic effects of selenium may differ significantly between men and

women contributes further to the complexity of this already challenging area of inquiry.

## Acknowledgements

The research of DJW on selenium and cancer prevention is supported by the Department of Defense Prostate Cancer Research Program. The authors also thank the Purdue University Center on Aging and the Life Course for the award of a Lynn Research Fellowship to ECC.

## References

- [1] M.P. Rayman, The importance of selenium to human health, *Lancet* 356 (2000) 233–241.
- [2] J.T. Rotruck, A.L. Pope, H.E. Ganther, A.B. Swanson, D.G. Hafeman, W.G. Hoekstra, Selenium: biochemical role as a component of glutathione peroxidase, *Science* 179 (1973) 588–590.
- [3] H.E. Ganther, Selenium metabolism, selenoproteins, and mechanisms of cancer prevention: complexities with thioredoxin reductase, *Carcinogenesis* 20 (1999) 1657–1666.
- [4] G.F. Combs Jr., W.P. Gray, Chemopreventive agents: selenium, *Pharmacol. Ther.* 79 (1998) 179–192.
- [5] C. Ip, H.J. Thompson, H.E. Ganther, Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland, *Cancer Epidemiol. Biomarkers Prev.* 9 (2000) 49–54.
- [6] C. Ip, C. Hayes, R.M. Budnick, H.E. Ganther, Chemical form of selenium, critical metabolites, and cancer prevention, *Cancer Res.* 51 (1991) 595–600.
- [7] M. Vinceti, S. Rovesti, M. Bergomi, G. Vivoli, The epidemiology of selenium and human cancer, *Tumori* 86 (2000) 105–118.
- [8] M. Garland, M.J. Stampfer, W.C. Willett, D.J. Hunter, The epidemiology of selenium and human cancer, in: B. Frei (Ed.), *Natural Antioxidants in Human Health and Disease*, Academic Press, 1994, pp. 263–286.
- [9] L.C. Clark, G.F. Combs Jr., B.W. Turnbull, E.H. Slate, D.K. Chalker, J. Chow, L.S. Davis, R.A. Glover, G.F. Graham, E.G. Gross, A. Krongrad, J.L. Leshner Jr., H.K. Park, B.B. Sanders Jr., C.L. Smith, J.R. Taylor, The nutritional prevention of cancer with selenium 1983–1993: a randomized clinical trial, *J. Am. Med. Assoc.* 276 (1996) 1957–1963.
- [10] G.F. Combs Jr., J. Lu, Selenium as a cancer prevention agent, in: D.L. Hatfield (Ed.), *Selenium, Its Molecular Biology and Role in Human Health*, Kluwer Academic Publishers, Norwell, MA, 02061, 2001, pp. 205–217.
- [11] F.J. Kok, A.M. deBruijn, A. Hofman, R. Vermeeren, H.A. Valkenburg, Is serum selenium a risk factor for cancer in men only? *Am. J. Epidemiol.* 125 (1987) 12–16.

- [12] J.T. Salonen, R. Salonen, R. Lappeteläinen, P.H. Maenpää, G. Alfthan, P. Puska, Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data, *Br. Med. J.* 290 (1985) 417-420.
- [13] W.C. Willett, B.F. Polk, J.S. Morris, M.J. Stampfer, S. Pressel, B. Rosner, J.O. Taylor, K. Schneider, C.G. Hames, Prediagnostic serum selenium and risk of cancer, *Lancet* 2 (1983) 130-134.
- [14] T.M. Wizenmann, M.L. Pardue (Eds.), *Exploring the Biological Contributions to Human Health: Does Sex Matter?* National Academy Press, 2001.
- [15] V.W. Pinn, Sex and gender factors in medical studies, *J. Am. Med. Assoc.* 289 (2003) 397-400.
- [16] P. Knekt, A. Aromaa, J. Maatela, G. Alfthan, R.K. Aaran, M. Hakama, T. Hakulinen, R. Peto, L. Teppo, Serum selenium and subsequent risk of cancer among Finnish men and women, *J. Natl. Cancer Inst.* 82 (1990) 864-868.
- [17] J. Ringstad, B.K. Jacobsen, S. Tretli, Y. Thomassen, Serum selenium concentration associated with risk of cancer, *Clin. Pathol.* 41 (1988) 454-457.
- [18] S. Ujii, H. Kikuchi, The relation between serum selenium value and cancer in Miyagi, Japan: 5-year follow up study, *Tohoku J. Exp. Med.* 196 (2002) 99-109.
- [19] M.H. Criqui, S. Bangdiwala, D.S. Goodman, W.S. Blaner, J.S. Morris, S. Kritchevsky, K. Lippel, I. Mebane, H.A. Tyroler, Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study, *Ann. Epidemiol.* 1 (1991) 385-393.
- [20] M. Kornitzer, F. Valente, D. De Bacquer, J. Neve, G. De Backer, Serum selenium and cancer mortality: a nested case-control study within an age- and sex-stratified sample of the Belgian adult population, *Eur. J. Clin. Nutr.* 58 (2004) 98-104.
- [21] M. Garland, J.S. Morris, M.H. Stampfer, G.A. Colditz, V.L. Spate, C.K. Baskett, B. Rosner, F.E. Speizer, W.C. Willett, D.J. Hunter, Prospective study of toenail selenium levels and cancer among women, *J. Natl. Cancer Inst.* 87 (1995) 497-505.
- [22] P.A. van den Brandt, M.P.A. Zeegers, P. Bode, R.A. Goldbohm, Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study, *Cancer Epidemiol. Biomarkers Prev.* 12 (2003) 866-871.
- [23] K. Yoshizawa, W.C. Willett, J.S. Morris, M.J. Stampfer, D. Spiegelman, E.B. Rimm, E.J. Giovannucci, Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer, *J. Natl. Cancer Inst.* 90 (1998) 1219-1224.
- [24] T.J. Hartman, D. Albanes, P. Pietinen, A.M. Hartman, M. Rautalahti, J.A. Tangrea, P.R. Taylor, The association between baseline vitamin E, selenium, and prostate cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, *Cancer Epidemiol. Biomarkers Prev.* 7 (1998) 335-340.
- [25] G.E. Goodman, S. Schaffer, D.D. Bankson, M.P. Hughes, G.S. Omenn, The Carotene Retinol Efficacy Trial (CARET) Co-Investigators Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk, *Cancer Epidemiol. Biomarkers Prev.* 10 (2001) 1069-1076.
- [26] A.M.Y. Nomura, J. Lee, G.N. Stemmermann, G.F. Combs, Serum selenium and subsequent risk of prostate cancer, *Cancer Epidemiol. Biomarkers Prev.* 9 (2000) 883-887.
- [27] K.J. Helzlsouer, H.Y. Huang, A.J. Alberg, S. Hoffman, A. Burke, E.P. Norkus, J.S. Morris, G.W. Comstock, Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer, *J. Natl. Cancer Inst.* 92 (2000) 2018-2023.
- [28] J.D. Brooks, E.J. Metter, D.W. Chan, L.J. Sokoll, P. Landis, W.G. Nelson, D. Muller, R. Annes, H.B. Carter, Plasma selenium level before diagnosis and the risk of prostate cancer development, *J. Urol.* 166 (2001) 2034-2038.
- [29] J.F. Dorgan, A. Sowell, C.A. Swanson, N. Potischman, R. Miller, N. Schussler, H.E. Stephenson, Relationships of serum carotenoids, retinal, alpha-tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States), *Cancer Causes Control* 9 (1998) 89-97.
- [30] P.A.H. van Noord, H.J.A. Collette, M.J. Maas, F. De Waard, Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort-nested case-referent study among women screened in the DOM project, *Int. J. Epidemiol.* 16 (1987) 318-322.
- [31] P.A.H. van Noord, M.J. Maas, I. Van der Tweel, C. Collette, Selenium and the risk of postmenopausal breast cancer in the DOM cohort, *Breast Cancer Res. Treat.* 25 (1993) 11-19.
- [32] K. Overvad, D.Y. Wang, J. Olsen, D.S. Allen, E.B. Thorling, R.D. Bulbrook, J.L. Hayward, Selenium in human mammary carcinogenesis: a case-cohort study, *Eur. J. Cancer* 27 (1991) 900-902.
- [33] P.A. van den Brandt, R.A. Goldbohm, P. van't Veer, P. Bode, E. Dorant, R.J.J. Hermus, F. Sturmans, Toenail selenium levels and the risk of breast cancer, *Am. J. Epidemiol.* 140 (1994) 20-26.
- [34] D.J. Hunter, J.S. Morris, M.J. Stampfer, G.A. Colditz, F.E. Speizer, W.C. Willett, A prospective study of selenium status and breast cancer risk, *J. Am. Med. Assoc.* 264 (1990) 1128-1131.
- [35] G.W. Comstock, A.J. Alberg, H.Y. Huang, K. Wu, A.E. Burke, S.C. Hoffman, E.P. Norkus, M. Gross, R.G. Cutler, J.S. Morris, V.L. Spate, K.J. Helzlsouer, The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha-tocopherol, selenium, and total peroxyl radical absorbing capacity, *Cancer Epidemiol. Biomarkers Prev.* 6 (1997) 907-916.
- [36] P.A. van den Brandt, R.A. Goldbohm, P. van't Veer, P. Bode, E. Dorant, R.J. Hermus, F. Sturmans, A prospective cohort study on selenium status and the risk of lung cancer, *Cancer Res.* 53 (1993) 4860-4865.
- [37] P.A. van den Brandt, R.A. Goldbohm, P. van't Veer, P. Bode, E. Dorant, R.J.J. Hermus, F. Sturmans, A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer, *J. Natl. Cancer Inst.* 85 (1993) 224-229.
- [38] P.G.J. Burney, G.W. Comstock, J.S. Morris, Serologic precursors of cancer: serum micronutrients and the subsequent



- 731 risk of pancreatic cancer, *Am. J. Clin. Nutr.* 49 (1989) 895-  
732 900.
- 733 [39] A.J. Duffield-Lillico, M.E. Reid, B.W. Turnbull, G.F.  
734 Combs Jr., E.H. Slate, L.A. Fischbach, J.R. Marshall, L.C.  
735 Clark, Baseline characteristics and the effect of selenium  
736 supplementation on cancer incidence in a randomized clinical  
737 trial: a summary report of the Nutritional Prevention of Cancer  
738 Trial, *Cancer Epidemiol. Biomarkers Prev.* 11 (2002) 630-  
739 639.
- 740 [40] A.J. Duffield-Lillico, B.L. Dalkin, M.E. Reid, B.W. Turnbull,  
741 E.H. Slate, E.T. Jacobs, J.R. Marshall, L.C. Clark, Nutritional  
742 Prevention of Cancer Study Group Selenium supplementation,  
743 baseline plasma selenium status and incidence of prostate  
744 cancer: an analysis of the complete treatment period of the  
745 Nutritional Prevention of Cancer Trial, *BJU Int.* 91 (2003)  
746 608-612.
- 747 [41] W.J. Blot, J.Y. Li, P.R. Taylor, W. Guo, S. Dawsey, G.Q.  
748 Wang, C.S. Yang, S.F. Zheng, M. Gail, G.Y. Li, Y. Yu,  
749 B.Q. Liu, J. Tangrea, Y.H. Sun, F. Liu, J.F. Fraumeni, Y.H.  
750 Zhang, B. Li, Nutrition intervention trials in Linxian, China:  
751 supplementation with specific vitamin/mineral combinations,  
752 cancer incidence, and disease-specific mortality in the general  
753 population, *J. Natl. Cancer Inst.* 85 (1993) 1483-1492.
- 754 [42] S.D. Mark, Y.L. Qiao, S.M. Dawsey, Y.P. Wu, H. Katki, E.W.  
755 Gunter, J.F. Fraumeni, W.J. Blot, Z.W. Dong, P.R. Taylor,  
756 Prospective study of serum selenium levels and incident  
757 esophageal and gastric cancers, *J. Natl. Cancer Inst.* 92 (2000)  
758 1753-1763.
- 759 [43] X.N. Zou, P.R. Taylor, S.D. Mark, A. Chao, W. Wang, S.M.  
760 Dawsey, Y.P. Wu, Y.L. Qiao, S.F. Zheng, Seasonal variation  
761 of food consumption and selected nutrient intake in Linxian,  
762 a high risk area for esophageal cancer in China, *Int. J. Vitam.*  
763 *Nutr. Res.* 72 (2002) 375-382.
- 764 [44] S.E. Benner, W.K. Hong, Clinical chemoprevention:  
765 developing a cancer prevention strategy, *J. Natl. Cancer Inst.*  
766 85 (1993) 1446-1447.
- 767 [45] P. Knekt, J. Marniemi, L. Teppo, M. Hellewaara, A. Aromaa,  
768 Is low selenium status a risk factor for lung cancer? *Am J.*  
769 *Epidemiol.* 148 (1998) 975-982.
- 770 [46] D. Ratnasinghe, J.A. Tangrea, M.R. Forman, T. Hartman,  
771 E.W. Gunter, Y.L. Qiao, S.X. Yao, M.J. Barrett, C.A. Giffen,  
772 Y. Erozan, M.S. Tockman, P.R. Taylor, Serum tocopherols,  
773 selenium and lung cancer risk among tin miners in China,  
774 *Cancer Causes Control* 11 (2000) 129-135.
- 775 [47] T.J. Hartman, P.R. Taylor, G. Alfthan, R. Fagerstrom, J.  
776 Virtamo, S.D. Mark, M. Virtanen, M.J. Barrett, D. Albanes,  
777 Toenail selenium concentration and lung cancer in male  
778 smokers (Finland), *Cancer Causes Control* 13 (2002) 923-  
779 928.
- 780 [48] J. Virtamo, E. Valkeila, G. Alfthan, S. Punsar, J.K. Huttunen,  
781 M.J. Karvonen, Serum selenium and risk of cancer: a  
782 prospective follow-up of nine years, *Cancer* 60 (1987) 145-  
783 148.
- 784 [49] G. Fex, B. Pettersson, B. Akesson, Low plasma selenium  
785 as a risk factor for cancer death in middle-aged men, *Nutr.*  
786 *Cancer* 10 (1987) 221-229.
- [50] A. Nomura, L.K. Heilbrun, J.S. Morris, G.N. Stemmermann, 787  
Serum selenium and the risk of cancer, by specific sites: case- 788  
control analysis of prospective data, *J. Natl. Cancer Inst.* 79 789  
(1987) 103-108. 790
- [51] M.R. Karagas, E.R. Greenberg, D. Nierenberg, T.A. Stukel, 791  
J.S. Morris, M.M. Stevens, J.A. Baron, Risk of squamous cell 792  
carcinoma of the skin in relation to plasma selenium, alpha- 793  
tocopherol, beta-carotene, and retinol: a nested case-control 794  
study, *Cancer Epidemiol. Biomarkers Prev.* 6 (1997) 25-29. 795
- [52] D.S. Michaud, T.J. Hartman, P.R. Taylor, P. Pietinen, G. 796  
Alfthan, J. Virtamo, D. Albanes, No association between 797  
toenail selenium levels and bladder cancer risk, *Cancer* 798  
*Epidemiol. Biomarkers Prev.* 11 (2002) 1505-1506. 799
- [53] M.W. Yu, I.S. Horng, K.H. Hsu, Y.C. Chiang, Y.F. Liaw, 800  
C.J. Chen, Plasma selenium levels and risk of hepatocellular 801  
carcinoma among men with chronic hepatitis virus infection, 802  
*Am. J. Epidemiol.* 150 (1999) 367-374. 803
- [54] K.J. Helzlsouer, A.J. Alberg, E.P. Norkus, J.S. Morris, 804  
S.C. Hoffman, G.W. Comstock, Prospective study of serum 805  
micronutrients and ovarian cancer, *J. Natl. Cancer Inst.* 88 806  
(1996) 32-37. 807
- [55] R.M. Bostick, J.D. Potter, D.R. McKenzie, T.A. Sellers, L.H. 808  
Kushi, K.A. Steinmetz, A.R. Folsom, Reduced risk of colon 809  
cancer with high intake of vitamin E: the Iowa women's 810  
health study, *Cancer Res.* 53 (1993) 4230-4237. 811
- [56] A.M. Batieha, H.K. Armenian, E.P. Norkus, J.S. Morris, 812  
V.E. Spate, G.W. Comstock, Serum micronutrients and the 813  
subsequent risk of cervical cancer in a population-based 814  
nested case-control study, *Cancer Epidemiol. Biomarkers* 815  
*Prev.* 2 (1993) 335-339. 816
- [57] S.E. Schober, G.W. Comstock, K.J. Helzlsouer, R.M. Salkeld, 817  
J.S. Morris, A.A. Rider, R. Brookmeyer, Serologic precursors 818  
of cancer. I. Prediagnostic serum nutrients and colon cancer 819  
risk, *Am. J. Epidemiol.* 126 (1987) 1033-1041. 820
- [58] R.J. Coates, N.S. Weiss, J.R. Daling, J.S. Morris, R.F. Labbe, 821  
Serum levels of selenium and retinol and the subsequent risk 822  
of cancer, *Am. J. Epidemiol.* 128 (1988) 515-523. 823
- [59] M.S. Menkes, G.W. Comstock, J.P. Vuilleumier, K.J. Helzlsouer, 824  
A.A. Rider, R. Brookmeyer, Serum beta-carotene, vitamins 825  
A and E, selenium, and the risk of lung cancer, *N. Engl. J.* 826  
*Med.* 315 (1986) 1250-1254. 827
- [60] K.J. Helzlsouer, G.W. Comstock, J.S. Morris, Selenium, 828  
lycopene, alpha-tocopherol, beta-carotene, retinol, and 829  
subsequent bladder cancer, *Cancer Res.* 49 (1989) 6144-6148. 830
- [61] W. Zheng, W.J. Blot, E.L. Diamond, E.P. Norkus, V. Spate, 831  
J.S. Morris, G.W. Comstock, Serum micronutrients and the 832  
subsequent risk of oral and pharyngeal cancer, *Cancer Res.* 833  
53 (1993) 795-798. 834
- [62] R.A. Breslow, A.J. Alberg, K.J. Helzlsouer, T.L. Bush, 835  
E.P. Norkus, J.S. Morris, V.E. Spate, G.W. Comstock, 836  
Serological precursors of cancer: malignant melanoma, basal 837  
and squamous cell skin cancer, and prediagnostic levels 838  
of retinol, beta-carotene, lycopene, alpha-tocopherol, and 839  
selenium, *Cancer Epidemiol. Biomarkers Prev.* 4 (1995) 837-  
840 842. 841
- [63] J.T. Salonen, G. Alfthan, J.K. Huttunen, P. Puska, Association 842  
between serum selenium and the risk of cancer, *Am. J.* 843  
*Epidemiol.* 120 (1984) 342-349. 844



- [64] K. Wallace, T. Byers, J.S. Morris, B.F. Cole, E.R. Greenberg, J.A. Baron, A. Gudino, V. Spate, M.R. Karagas, Prediagnostic serum selenium concentration and the risk of recurrent colorectal adenoma: a nested case-control study, *Cancer Epidemiol. Biomarkers Prev.* 12 (2003) 464–467.
- [65] M. Kabuto, H. Imai, C. Yonezawa, K. Neriisi, S. Akiba, H. Kato, T. Suzuki, C.E. Land, W.J. Blot, Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan, *Cancer Epidemiol. Biomarkers Prev.* 3 (1994) 465–469.
- [66] I. Peleg, S. Morris, C.G. Hames, Is serum selenium a risk factor for cancer? *Med. Oncol. Tumor Pharmacother.* 2 (1985) 157–163.
- [67] M.P.A. Zeegers, R.A. Goldbohm, P. Bode, P.A. van den Brandt, Prediagnostic toenail selenium and risk of bladder cancer, *Cancer Epidemiol. Biomarkers Prev.* 11 (2002) 1292–1297.
- [68] E.A. Zang, E.L. Wynder, Differences in lung cancer risk between men and women: examination of the evidence, *J. Natl. Cancer Inst.* 88 (1996) 183–192.
- [69] D.G. Guinee Jr., W.D. Travis, G.E. Trivers, et al., Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 antibodies and C-erbB-2 expression, *Carcinogenesis* 16 (1995) 993–1002.
- [70] S. Mollerup, D. Ryberg, A. Hewer, D.H. Phillips, A. Haugen, Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients, *Cancer Res.* 59 (1999) 3317–3320.
- [71] Q. Wei, L. Cheng, C.I. Amos, L.-E. Wang, Z. Guo, W.K. Hong, M.R. Spitz, Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study, *J. Natl. Cancer Inst.* 92 (2000) 1764–1772.
- [72] J.S. Morris, T. Rohan, C.L. Soskolne, M. Jain, T.L. Horsman, V.L. Spate, C.K. Baskett, M.M. Mason, T.A. Nichols, Selenium status and cancer mortality in subjects residing in four Canadian provinces, *J. Radioanal. Nuclear Chem.* 249 (2001) 421–427.
- [73] J.W. Finley, R.L. Kincaid, Effect of sex and time of sampling on selenium and glutathione peroxidase activity in tissues of mature rats, *Biol. Trace Elem. Res.* 29 (1991) 181–191.
- [74] NCI, DCPC Chemoprevention Branch and Agent Development Committee, Clinical development plan: l-selenomethionine, *J. Cell Biochem.* 26S (1996) 202–218.
- [75] P.A. van den Brandt, R.A. Goldbohm, P. van't Veer, P. Bode, R.J.J. Hermus, F. Sturmans, Predictors of toenail selenium levels in men and women, *Cancer Epidemiol. Biomarkers Prev.* 2 (1993) 107–112.
- [76] C.A. Swanson, M.P. Longnecker, C. Veillon, S.M. Howe, O.A. Levander, P.R. Taylor, P.A. McAdam, C.C. Brown, M.J. Stampfer, W.C. Willett, Selenium intake, age, gender, and smoking in relation to indices of selenium status of adults residing in a seleniferous area, *Am. J. Clin. Nutr.* 52 (1990) 858–862.
- [77] B. Patterson, C.C. Veillon, P. Taylor, K. Patterson, O.A. Levander, Selenium metabolism in humans differs by gender: results from a stable isotope tracer study, *FASEB J.* 15 (2001) A969.
- [78] E.M. Rodrigue Zrodriguez, M.T. San Zalaes, C. Dia Zromero, Urinary selenium status of healthy people, *Eur. J. Clin. Chem. Clin. Biochem.* 33 (1995) 127–133.
- [79] M.R. Kafai, V. Ganji, Sex, age, geographical location, smoking, and alcohol consumption influence serum selenium concentrations in the USA: third National Health and Nutrition Examination Survey, 1988–1994, *J. Trace Elem. Med. Biol.* 17 (2003) 13–18.
- [80] D.J. Waters, S. Shen, D.M. Cooley, D.G. Bostwick, J. Qian, G.F. Combs Jr., L.T. Glickman, C. Oteham, D.L. Schlittler, J.S. Morris, Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate, *J. Natl. Cancer Inst.* 95 (2003) 237–241.
- [81] W. Mertz, The essential trace elements, *Science* 213 (1981) 1332–1338.
- [82] W.C. Willett, M.J. Stampfer, Selenium and human cancer: epidemiological aspects and implications for clinical trials, *J. Am. Coll. Toxicol.* 5 (1986) 29–36.



# Cancer

with [Erin Breitenbach](#)

Your Guide to one of [hundreds of sites](#)

[Home](#) · [Articles](#) · [Forums](#) · [Chat](#) · [Newsletters](#) · [Help](#)

## Subjects

### ESSENTIALS

- [Top Cancer Books & Videos](#)
- [Top 10 Cancer Risks](#)
- [New Cancer Drugs Approved By The FDA](#)
- [3 Ways to Reduce Your Cancer Risk](#)
- [Guide to Making Treatment Decisions](#)

[Bladder Cancer](#)

[Bone Cancer](#)

[Brain & CNS Tumors](#)

[Breast Cancer](#)

[Colon Cancer](#)

[Leukemia](#)

[Liver Cancer](#)

[Lung Cancer](#)

[Lymphoma](#)

[Oral Cancer](#)

[Ovarian Cancer](#)

[Pancreatic Cancer](#)

[Prostate Cancer](#)

## Does Selenium Prevent Prostate Cancer?

By: Kathleen Wildasin

David J. Waters, DVM, PhD, Director of the Gerald P. Murphy Cancer Foundation and Professor of Comparative Oncology at Purdue University, is leading a research team in the investigation of how selenium, a nutrient essential to the functioning of several metabolically important enzymes, inhibits the development of prostate cancer.

"Using elderly beagles to mimic 65-year-old men, we evaluated the effect of selenium on prostate cells in an appropriate context ... in vivo in an aging prostate gland," Waters said.

Although most information on the mechanisms of anticancer agents has been gleaned from studies using animal tumor models, studying prostate cancer in the laboratory has been hampered by the fact that only one non-human species, the dog, develops this cancer spontaneously and with appreciable frequency.

The research of Waters and colleagues complements the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a study initiated in 2001 by the National Cancer Institute to evaluate whether selenium and/or vitamin E decreases the incidence of human prostate cancer. The largest prostate cancer prevention study ever undertaken, SELECT will evaluate more than 32,000 men during a 12-year period. The Murphy Foundation is one of more than 400 sites in North America that will enroll men into the SELECT Trial.

"In this study supported by the Department of Defense Prostate Cancer Research Program, we found that 7 months of daily oral supplementation, using the same form and dose of selenium currently being used in SELECT, significantly reduced the accumulation of DNA damage within prostate cells," Waters said.

[Skin Cancer](#)

[Stomach Cancer](#)

[Testicular Cancer](#)

[Thyroid Cancer](#)

[Uterine Cancer](#)

[First Steps](#)

[Treatment Centers](#)

[Doctor Search](#)

[Support Groups](#)

[Support Hotlines](#)

[Glossaries](#)

[Financial](#)

[Treatment Options](#)

[Alternative Med](#)

[Clinical Trials](#)

[Side-Effects](#)

[Subject Library](#)

[All articles on this topic](#)

In the February 5, 2003 issue of the Journal of the National Cancer Institute, the group also reported that daily selenium supplementation was accompanied by a two-fold increase in prostate cell apoptosis. Apoptosis, an orderly process of cell death, can remove damaged cells from the prostate, which may lower the risk of cancer.

"Although several previous studies have shown that selenium can induce apoptosis in the cell culture laboratory, our results represent the most convincing evidence to date that DNA damage and apoptosis are selenium-responsive events within the prostate," Waters said.

The long-term research goal of Dr. Waters' comparative oncology team is to accelerate the development and application of effective cancer prevention strategies that will benefit both people and pet animals who are at high risk of developing cancer.

For more information regarding this article, contact Kathleen Wildasin at [kwildasin@insightbb.com](mailto:kwildasin@insightbb.com).

For more information regarding research on selenium and prostate cancer, visit the Murphy Foundation website ([www.gpmcf.org](http://www.gpmcf.org)), under the section "About Selenium."

*Bio: Kathleen Wildasin is a full-time freelance medical/science writer and editor. She holds B.A. degrees in biology and music theory/composition from Indiana University and the University of Minnesota, respectively, and an M.A. degree in music theory from the University of Iowa. Her articles have been published in magazines, education manuals, newsletters, and online, and her medical thriller and short stories have received recognition in national writing competitions. She lives in Lexington, Kentucky.*

## Stay up-to-date!

Subscribe to our newsletter.

## ResultsAbout

New from  
**About.com!**

[Get Paid to Improve Search](#)

### SOURCES:

(1) Personal communication (telephone, e-mail) with Dr. David Waters (May 2003).

(2) Waters DJ, Shen S, Cooley DM, et al. Effects of Dietary Selenium Supplementation on DNA Damage and Apoptosis in Canine Prostate. J Natl Cancer Inst 2003;95(3):237-241.

(3) Jennifer Warner, Selenium May Fight Prostate Damage. WebMD Medical News, February 2003.

(4) Jodi Knapik, Aultman Hospital Enrolling Men in Prostate Cancer Prevention Trial. Aultman News Press Release, accessed May 7, 2003.

Vitamins, minerals,  
supplements,  
and herbs

## Good News for **Men (and Dogs)**

With the help of some elderly beagles, experts discover an easy way to prevent prostate cancer.

BY SUSAN EDMISTON

Men, take note: The evidence for an easy, inexpensive way to prevent your number-one malignancy—prostate cancer—has reached critical mass. Prostate cancer strikes nearly 200,000 men each year and kills more than 30,000, and it can devastate a man's sex life. But you may be able to avoid that fate by taking a simple daily supplement of the mineral selenium.

In fact, the evidence for selenium has swelled into a tide even the FDA couldn't ignore. Last February the agency, notoriously reluctant to give any supplement its imprimatur, allowed health claims to be made for selenium, stating that the mineral may reduce the risk of certain cancers. Although it permitted only a qualified claim—research has yet to determine exact dosages and other factors that may affect the supplement's effectiveness—the agency's action put selenium on the map as one of the most powerful weapons in our anti-cancer arsenal.


Research first linked higher levels of selenium to reduced cancer risk in the 1960s. But the results of a ten-year study, published in 1996, thrust the mineral into the spotlight. The late Larry Clark, then associate professor of

epidemiology at the University of Arizona Cancer Center, had done a series of studies linking skin cancer to low selenium levels and decided to put his theory to the ultimate test: a double-blind, placebo-controlled study. For an average of four and a half years, 1,312 volunteers took either brewer's yeast tablets containing 200 micrograms of selenium or placebos.

Clark was surprised to find that the selenium had no effect on the skin cancers he was studying. But, as another selenium expert put it, "Then serendipity stepped in." Poring over his data,

whopping 63 percent lower risk of prostate cancer among the selenium-takers. (The study found no decrease in cancers for women, but since it focuses primarily on men—as does most subsequent selenium research—the jury's still out on whether women can benefit from supplements, too.)

Other researchers rushed to follow Clark's trail. In 1987, at Harvard, 33,737 male health professionals were asked to send in their toenail clippings, a measure of long-term selenium intake. Four years later, when the researchers matched the men to their clippings,



Beagles get prostate cancer, too, which is why they're part of a pivotal study on selenium.

Clark noticed that the three leading cancers in men—lung, prostate, and colon—were significantly lower in the people taking selenium. He redesigned the study to collect more complete information and ultimately found a moderate decrease in cancer overall, but a

they found that the rate of prostate cancer had decreased by one-half to two-thirds in those with the highest selenium levels.

But perhaps the most exciting evidence of selenium's powers comes from a bunch of elderly beagles. As a



comparative oncologist (an expert in cancers affecting both humans and animals), David Waters, of Purdue University, knew that beagles also tend to develop prostate cancer with age, and that selenium had been shown to lower the risk in men. But he wanted to know *how* selenium worked its magic. So he assembled 49 dogs that were roughly equivalent in age to 65-year-old men and gave 39 of them 200 micrograms of selenium (twice what most Americans

apoptosis in the prostate tissue of the selenium-supplemented dogs as in the untreated beagles.

Does this mean men should all immediately begin taking 200 micrograms of selenium a day?

Many experts say yes, among them pioneering physician Dean Ornish, in Sausalito, California. "If a drug company came out with a medication that could reduce the risk of cancer to this degree, just about every doctor in the

"If a drug company came out with a medication that could reduce the risk of cancer to this degree, just about every doctor in the country would prescribe it."

get from their daily diet). They also nibbled a brand of dog food that contains trace levels of selenium. The other ten pooches ate only the dog food.

The results, published last year in *Journal of the National Cancer Institute*, were impressive. After seven months, dogs who chewed selenium supplements along with their daily chow fared much better than those who didn't. Among the untreated dogs, nearly 80 percent of their prostate cells had extensive DNA damage, compared with 57 percent of cells from animals who got the extra selenium. When scientists examined the prostate tissue of all the dogs, they didn't find greater antioxidant activity in the selenium-takers—the mechanism they expected to be responsible for curbing cell damage—but they did find a much higher level of something called apoptosis.

Apoptosis is a normal biological process that, in effect, helps damaged cells commit suicide. When cells deteriorate or go haywire because of radiation, viral infection, aging, or the kind of aberrant growth that occurs with cancer, this process shuts them down, limiting the damage they can do. Waters' group found twice the level of

country would prescribe it," he says. "The potential benefit is great, the cost is very low, and so are the side effects and risks." Ornish's soon-to-be-reported Prostate Cancer Lifestyle Trial includes selenium supplements along with a low-fat plant-based diet and other cancer-reducing strategies.

John Finley, a scientist at the Human Nutrition Research Center in Grand Forks, North Dakota, also thinks men should be taking a daily supplement with 100 to 200 micrograms of selenium. (Until more research is done, it can't hurt for women to hedge their

bets against cancer with a supplement, too.) Most people have blood levels of selenium of about 120 mcg just from diet alone, says Finley, but it takes around 300 mcg to get the benefits.

Some experts recommend even more. Stephen Strum, former medical director of the Prostate Cancer Research Institute in Los Angeles, thinks it's perfectly safe to take daily doses in the 400 to 800 mcg range—the amount physicians routinely recommend in England. But don't overdo it. In doses above 1,000 micrograms, selenium can lead to a disease called selenosis, which may cause neurological problems, hair loss, and deformed nails. Anyone taking large amounts should watch for side effects—oddly enough, the first sign that you may be headed toward selenosis is a garlicky smell on your breath and skin—and work with a physician to find the right dosage.

Some experts think selenium might work best when taken along with vitamin E. A vast ten-year study, called SELECT (Selenium and Vitamin E Cancer Prevention Trial), sponsored by the National Cancer Institute, was launched in 2001 to find out. In the meantime, you can't go wrong with a daily dose of both supplements.

Tell your friends about them, too—including any beagles you know. **A**

Susan Edmiston is a contributing writer.


## >>> Selenium User's Guide

**What is it?** A trace mineral that's been shown to prevent prostate cancer, and possibly other cancers as well.

**Dosage:** Many experts recommend a multivitamin with 100 to 200 micrograms of selenium. But daily doses in the 400 to 800 mcg range are considered safe, too.

**Risks:** In amounts above 1,000 mcg, the mineral can lead to a disease called selenosis, which causes neurological problems, hair loss, and deformed nails.

—S.E.



# PROSTATE CANCER HOT SHEET

**Us Too! INTERNATIONAL**

**OCTOBER 2003**

## MORTALITY FROM FOUR LEADING CANCERS CONTINUES TO FALL IN US

Mortality from the four most common cancers in the US — lung, breast, prostate, and colorectal — continued to drop in the late 1990s, according to a report released Tuesday in the *Journal of the National Cancer Institute*.

Mortality for all cancer sites combined started to drop in 1994 and stabilized from 1998 through 2000, indicate the findings from the "Annual Report to the Nation on the Status of Cancer, 1975-2000." The report is a joint effort of many US health groups including the Centers for Disease Control and Prevention (CDC) and the American Cancer Society.

"This report shows that we have made some progress in reducing the burden of cancer in the US, but much still needs to be done to reach the Healthy People 2010 goals — including wider application of what science has shown to be effective in preventing, screening, and treating cancer," CDC director Julie Gerberding said in a statement.

Analysis of data from state and metropolitan area cancer registries revealed that incidence rates for all cancer sites increased between 1975 and 1992 and then dropped between 1992 and 1995, lead author Dr. Hannah K. Weir, from the Atlanta-based CDC, and colleagues note. Rates stabilized between 1995 and 2000.

The apparent stability in this most recent period was actually the result of two divergent trends, the researchers note. Although the incidence of lung cancer among men continued to fall, this trend was offset by a rise in new cases of breast and prostate cancer.

Death rates from all cancer sites started  
(continued on page 5)

## THE OUTDOOR CHANNEL PARTNERS WITH Us Too! TO FIGHT PROSTATE CANCER

The Outdoor Channel, a subsidiary of Outdoor Channel Holdings, Inc., and *Us Too! INTERNATIONAL* announced today a commitment to join forces in the war against prostate cancer. Executives from both organizations met to lock in the agreement at The National Conference on Prostate Cancer held in September in Burbank, California and release the news on the first day of National Prostate Cancer Awareness Week.

Based in Temecula, CA, The Outdoor Channel is a national cable network



dedicated to providing the best in traditional outdoor programming to America's sixty million anglers and hunters. The Outdoor Channel is available to nearly sixty million homes in the U.S. through a combination of cable networks and satellite providers. The network recently announced its launch to an international audience, reaching nearly eight million homes in Latin America. For more information, visit The Outdoor Channel's web site at [www.outdoorchannel.com](http://www.outdoorchannel.com).

The partnership calls on The Outdoor Channel to lend its resources in an  
(continued on page 8)

## BROTHERS, NOT FATHER, HAVE MORE AFFECT ON PROSTATE CANCER

Men are more at risk for prostate cancer if their brother — rather than their father — has the disease, according to new research. Researchers say this new finding may suggest that the risk is related to shared environmental factors like diet.

Led by Deborah Watkins Bruner, Ph.D., at Fox Chase Cancer Center in Philadelphia, researchers analyzed 23 published studies. They found an increased risk of prostate cancer for men with a family history, but if the affected family member was a brother, the risk increased nearly threefold. Links between first-degree relatives (father, son or brother) and second-degree relatives (a grandfather or uncle) were examined to see which relationship posed the greatest risk. Researchers found the risk increased 1.8 fold when the affected relative was a second-degree family member and 2.1 fold when the relative with prostate cancer was a father.

Bruner says, "Unlike the maternal-child pattern we see with inherited breast cancers, a brother with prostate cancer was associated with a significantly increased risk of the disease compared to a father or any other relative with the disease." In addition to the environmental factors, she theorizes the age of onset of the disease may reveal a stronger genetic risk. Although more research is needed, she says a combination of genetic and environmental factors likely contribute to increased risk.

Bruner also says, "We need to assess the risk of disease associated with younger age [less than 65 or 70 years] of onset, dietary habits and lifestyle behaviors that may interact with inherited genes to increase prostate cancer risk."

Source: *International Journal of Cancer*

## PROSTATE CANCER NEWS You Can Use

*Us Too!* publishes a FREE e-mail based news service which provides updates on the latest prostate cancer related news. To subscribe or link to the archives simply visit the *Us Too!* Website: [www.ustoo.org](http://www.ustoo.org)

News items contained in *Us Too!* publications are obtained from various news sources and edited for inclusion. Where available, a point-of-contact is provided.

All references to persons, companies, products or services are provided for information only, and are not endorsements. Readers should conduct their own research into any person, company, product or service, and consult with their loved ones and personal physician before deciding upon any course of action.

THE *Us Too!* PROSTATE CANCER HOT SHEET IS MADE POSSIBLE BY AN UNRESTRICTED EDUCATION GRANT FROM

**AstraZeneca**

THE INFORMATION AND OPINIONS EXPRESSED IN THIS PUBLICATION ARE NOT ENDORSEMENTS OR RECOMMENDATIONS FOR ANY MEDICAL TREATMENT, PRODUCT, SERVICE OR COURSE OF ACTION BY *Us Too!* INTERNATIONAL, INC., ITS OFFICERS AND DIRECTORS, OR THE EDITORS OF THIS PUBLICATION. FOR MEDICAL, LEGAL OR OTHER ADVICE, PLEASE CONSULT PROFESSIONAL(S) OF YOUR CHOICE.

### *Us Too!* HEADQUARTERS STAFF

JOHN A. PAGE, FHMS, PRESIDENT AND CEO  
PAMELA BARRETT, DEVELOPMENT DIRECTOR  
JACQUELINE KONIECZKA, OFFICE ASSISTANT  
CRAIG KUREY, DIRECTOR OF OPERATIONS  
MARY BETH MICCUCI, CHAPTERS COORDINATOR  
DOROTHY WIENIECK, PATIENT INFORMATION ASSISTANT  
5003 FAIRVIEW AVENUE - DOWNERS GROVE, IL 60515  
PHONE: (630) 795-1002 / FAX: (630) 795-1602  
WEBSITE: [WWW.USTOO.ORG](http://WWW.USTOO.ORG)  
SUPPORT HOTLINE (OUTSIDE CHICAGO) 1-800-80-UsToo!

### *Us Too!* BOARD OF DIRECTORS:

LEWIS MUSGROVE, CHAIRMAN  
RUSS GOULD, VICE CHAIRMAN  
JOANN HARDY, SECRETARY  
JIM KJEFFERT, EdD, TREASURER  
JOHN A. PAGE, FHMS, PRESIDENT AND CEO

### DIRECTORS:

GREGORY BIELAWSKI  
RONALD W. FABRICK, DDS  
ROBERT HUSTEAD, MD  
DON LYNAM, PhD  
DANNY PARKER, PhD  
HARRY PINCHOT  
JOE PIPER  
JAMAL RASHEED  
CHARLES SELDEN

*Us Too!* INTERNATIONAL, INC.  
IS INCORPORATED IN THE STATE OF ILLINOIS  
AND RECOGNIZED AS A 501(c)(3)  
NOT-FOR-PROFIT CHARITABLE CORPORATION.  
DONATIONS / GIFTS TO *Us Too!* ARE TAX DEDUCTIBLE.  
COPYRIGHT 2003, *Us Too!* INTERNATIONAL, INC.

## RESEARCHERS ORGANIZE PROSTATE CANCER INTO GENETICALLY DISTINCT CATEGORIES

Daniel J. George, MD  
Veritas Medicine

With over 180,000 new cases of diagnosed each year, there is an enormous number of men with prostate cancer. But is it all the same disease?

The natural history of prostate cancer has taught us that a subset of men - roughly 30,000 each year - will die from this disease, despite our best treatment efforts. Another subset - perhaps as many as 90,000 cases each year - may be incidental and pose minimal risk to the patient. Why then do we classify all these cancers by the same name?

The Gleason score, or grade of prostate cancer, has been the most successful method to date for sub-classifying the disease. The Gleason score, however, is not based upon any molecular or genetic markers in prostate cancer. In this month's issue of the journal *Cancer Research*, investigators at the Dana-Farber Cancer Institute published an attempt to sub-classify prostate cancers by their genetic makeup. A technique known as single nucleotide polymorphisms, or SNP mapping, allows researchers to create a genetic fingerprint of tumors. Cancers with similar fingerprints are clustered together to create an overall genetic map.

The efforts of the Dana-Farber team represent one of the first to genetically sub-classify prostate cancer, but more work still needs to be done to get a complete picture of the different types of prostate cancer. The SNP mapping technique is likely to improve with greater technological breakthroughs, and the general principle of classifying tumors according to their genetic profile has been validated in other diseases such as lymphoma. Ultimately, a more accurate classification of prostate cancers should lead to treatments customized to certain types of prostate cancer, and perhaps target therapy more effectively.

### Reference:

ME Lieberfarb et al. Genome-wide Loss of Heterozygosity Analysis from Laser Capture Microdissected Prostate Cancer Using Single Nucleotide Polymorphic Allele (SNP) Arrays and a Novel Bioinformatics Platform ChipSNP. *Cancer Research* 63, 4781-4785 (2003).

## TREATMENT OF ORGAN CONFINED PROSTATE CANCER WITH THIRD GENERATION CRYOSURGERY: PRELIMINARY MULTICENTER EXPERIENCE

Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldgrun AS.

J Urol. 2003 Oct;170(4):1126-1130

### SUMMARY:

#### PURPOSE

Cryosurgical ablation of the prostate is 1 approach to the treatment of localized prostate cancer. Third generation cryosurgery uses gas driven probes that allow for a decrease in probe diameter to 17 gauge (1.5 mm). The safety, morbidity and preliminary prostate specific antigen (PSA) results of 122 cases are reported.

#### MATERIALS AND METHODS

A total of 106 patients have undergone percutaneous cryosurgery using a brachytherapy template with at least 12 months of PSA followup. Immediate and delayed morbidities were evaluated. PSA results at 3 and 12 months were recorded, and failure was defined as the inability to reach a nadir of 0.4 ng/ml or less.

#### RESULTS

Complications in patients undergoing primary cryosurgery included tissue sloughing (5%), incontinence (pads, 3%), urge incontinence/no pads (5%), transient urinary retention (3.3%) and rectal discomfort (2.6%). There were no cases of fistulas or infections. Postoperative impotence was 87% in previously potent patients. For patients who underwent salvage cryosurgery there were no fistulas reported and 2 (11%) patients required pads after salvage cryosurgery. A total of 96 (81%) patients achieved a PSA nadir of 0.4 ng/ml or less at 3 months of followup,

(continued on page 8)

# WHAT EVERY DOCTOR WHO TREATS MALE PATIENTS SHOULD KNOW

*Stephen B. Strum, MD*

Prostate cancer diagnosis clinical practice guidelines:

Every man should have an annual PSA and DRE starting at forty years of age. Men at risk due to family history of prostate cancer (brothers, fathers, uncles), men with family history of breast cancer (mothers, sisters, aunts) and black men should begin annual screening at age 35.

A PSA of 2.0 and over at any age should be investigated to rule out prostate cancer (PC).

A first step in investigation of PSA's elevated at 2.0 and above should be a free PSA percentage test.

- A free PSA percentage of over 25% is associated with a low risk of prostate cancer.
- A free PSA percentage of under 15% is associated with a higher risk of prostate cancer.
- A benign cause of an elevated PSA and a correspondingly low free PSA percentage would be prostatitis. Four to six weeks of Cipro or similar antibiotic should be prescribed prior to recommending a biopsy if prostatitis symptoms are noted or if expressed prostatic secretions (EPS) are consistent with prostatitis.
- BPH (benign prostate hyperplasia) does not cause a low free PSA percentage. It may cause an elevated PSA, however. So in the case of an elevated PSA but a high free PSA percentage, an estimate of gland volume by DRE or a transrectal ultrasound of the prostate may reveal findings consistent with a diagnosis of BPH.

Blood sampling for PSA determinations, done at least three months apart, and by the same

laboratory using the same testing procedure, are necessary to establish PSA velocity (PSAV) and PSA doubling time (PSADT).

- A PSAV that exceeds 0.75 ng/ml/yr is associated with a higher probability of PC.
- A PSADT of less than 12 years is associated with a higher probability of PC.

PSA's that bounce up and down are more indicative of benign processes than malignant processes.

PSA's that show a persistent rise over time, particularly three consecutive rises, three months apart are suspicious for prostate cancer regardless of the level of the PSA.

Gland volume in cubic centimeters (cc) multiplied by 0.066 yields the amount of PSA produced by a normal, non-malignant gland. Any amount of PSA in excess of this should be considered to be produced by a malignant process until proven otherwise.

## Pussycats vs. tigers:

Pussycats in general, have low PSA values (under 10) and long doubling times, as well as low PSA velocities. If a biopsy is done on a patient with a PSA that is under 10, the Gleason score often turns out to be (3,3). Depending on the calculated tumor volume, T-stage and other factors, many of these patients may be candidates for objectified observation as well as for any of the currently FDA approved local therapies. Patients who choose to monitor their disease status rather than seek immediate local treatment need to be vigilant and need to be aware that if disease progression is evident, they may need to consider a form of local treatment before the window of opportunity for successful local treatment slams shut.

Tigers in general, have high PSA's (over 10) OR very low PSA's associated with very aggressive, high Gleason score cancers. These are very dangerous because they often escape investigation for long periods of time since the PSA's appear to be in the so-called normal range. Investigating all PSA's 2.0

and over will help to catch these prostate cancers while they are still organ-confined and treatable with local therapies. The probability of spotting these low PSA/high Gleason score cancers is enhanced if patients and doctors monitor PSA levels over time to note any persistent increases even if the PSA is very low. High Gleason score cancers often have reverted to such a primitive state that they no longer secrete PSA into the blood. Therefore, in cases such as this, the normal guidelines for PSA velocity and doubling time may not be applicable.

## **SELECTED RESOURCES FOR PHYSICIANS AND PATIENTS:**

### On the Web:

The Prostate Cancer Research Institute (PCRI) web site at [www.pcri.org](http://www.pcri.org). This site has a wealth of information including the Prostate Cancer Address Book listing expert prostate cancer physicians, software tools, and articles and the newsletter INSIGHTS.

The Phoenix5 web site at [www.phoenix5.org](http://www.phoenix5.org). This is a vast resource for the prostate cancer student, with information on nearly every aspect of the disease as well as an excellent glossary, many first person stories and the prostate cancer journal of the webmaster who died of prostate cancer in June, 2003.

**Us Too! INTERNATIONAL** – Prostate Cancer Education and Support website at [www.ustoo.org](http://www.ustoo.org). The world's largest independent, charitable network of education and support groups for men with prostate cancer and their families.

### In print:

*"A Primer on Prostate Cancer, The Empowered Patient's Guide"* by Stephen B. Strum, MD and Donna Pogliano, copyright 2002. Available through **Us Too!** for \$20 (plus \$5 s&h) through the **Us Too!** website or by calling (317) 558-4858 and at web booksellers and fine bookstores everywhere. Everything you ever wanted to know about prostate cancer.



# AFRAID I HAVE BAD NEWS... TWELVE STEPS TO HANDLE A DISTURBING DIAGNOSIS

By Elizabeth Austin

AARP Magazine - May-June 2003

It's the bombshell everyone dreads. The doctor calls and asks you to visit so you can discuss your test results. Your biopsy has come back positive. Or your EKG is abnormal. Or your blood test revealed something questionable. Without warning and without preparation, you're suddenly battling a serious health problem.

What happens next? That depends partly on your individual situation. A cancer scare will bring one set of challenges and choices, and a life-threatening heart ailment will bring others. But experts say there are basic steps that all patients should take, no matter what illness they're facing. This 12-step plan will help you get the best possible care—and the greatest chance for a quick, successful recovery.

1. Start building your team. Don't try to get through this battle alone. Ask at least one trusted person to be your full-time advocate who can accompany you to doctor appointments, says Joni Rodgers, author of *Bald in the Land of Big Hair*, a memoir of her battle with lymphatic cancer. "You need someone who is objective and isn't going to hear just what they want to hear," she explains.

"Your best choice is someone who is not excitable or confrontational and who is good at taking notes," adds Marsha Hurst, Ph.D., director of the health advocacy program at Sarah Lawrence College in Bronxville, New York. If your sister gets hysterical, or your husband's ears hear only good news, ask a friend to step in.

You'll also need to designate an information manager, someone to return the 20 daily phone calls you'll soon be getting from concerned friends and relatives—or those half-forgotten acquaintances who want to hear all the gory details. Don't be timid about ducking out of distressing conversations. A good escape speech: "Although it means so much to me that you're interested, I'm not always able to talk about this. But I'll promise to keep you updated." Then give the friend's number to your information manager.

Call in outstanding favors when asking people to help; if you fed someone's goldfish for a week in 1982, that counts. "The definite skill that every survivor cultivates is the ability to assemble a team they can rely on," says Rodgers.

2. Don't let a gung-ho doctor rush you. Sometimes speed saves lives. When Rodgers was diagnosed with advanced cancer, her life depended on getting immediate treatment (starting the next day). "I had to depend on doctors to make a good decision in that moment," she explains. But whenever possible, take a few days, or even a couple of weeks, to ponder all your options—including the ones your physician may not know about. This is especially hard after you get hit with a diagnosis, and you're anxious. "I felt like I had a roach on me—get it off, get it off!" admits Rodgers. But jumping in to treatment too quickly—and without taking all of the steps outlined in this article—can lead to regret.

3. Take a hard look at your primary care doctor. If you've got a rare disease, the internist you've seen for years may be intrigued—but he's probably not the best physician to monitor your treatment. Make sure your doctor is up to speed on your particular condition. You can get the lowdown on him by calling your state board of medicine and checking his history and training at [www.healthgrades.com](http://www.healthgrades.com). Also, directly ask your doctor if he feels qualified to treat you, and if he regularly performs the surgical procedure you may need done. If he's not the expert you need, he should be happy to refer you to a specialist who's better able to handle your case, says Richard A. Wherry, M.D., a family physician in Dahlonega, Georgia. "I never worry about losing control, because that's not what this is about." If he can't admit his limitations, consider changing doctors—if your insurance plan is flexible enough to allow this on short notice.

4. Invest 40 bucks in a microcassette tape recorder. This will allow you to record your talks with your doctor. "You can listen to it when you're not so upset and also let your family or other doctors listen to it," says journalist Curtis Pesmen, who wrote about his battle with colon cancer in *Esquire*. (Having a verbatim record can also help bring another doctor up to speed when you're looking for a second opinion.) Also, buy a heavy-duty, hard-to-lose notebook, and hand it over to your advocate during appointments. Don't even think about trying to write while

you're listening to a doctor talk about your life. "It's like trying to take notes while you're being attacked by a dog," Rodgers says.

5. Tap two brains. Don't hesitate to get a second opinion—and don't feel uneasy about telling your doctor you want one. "When one of my patients gets a second opinion, only two things can happen, and they're both good," says Wherry, who is also on the Board of Directors of the American Academy of Family Physicians. "Either I'm right, or the other doctor finds something I didn't diagnose and the patient comes out ahead." Let statistics encourage you: In about one in five cases, the second opinion yields a different diagnosis, says Charles Inlander, president of the People's Medical Society, a consumer health advocacy group in Allentown, Pennsylvania. And even if the second doctor agrees with the diagnosis, she may have different ideas for the best treatment.

A political tip: Don't ask for a second opinion from another physician in your own doctor's practice; they're not likely to contradict each other. A doctor who works with a different hospital, preferably outside your insurance network, is usually the most unbiased choice. (Many insurance plans will pay part of the cost of consulting a specialist outside your network.)

When you're investigating treatment options with each doctor, make sure you're getting the whole story. "Ask 'What is the most aggressive treatment, what's more conservative, and what are the points in between?'" Inlander advises. Then ask the specialist what he or she thinks is the smartest strategy and why. Follow up by asking whether your insurance company covers the other options. If it doesn't, ask why.

You're likely to wind up with some conflicting opinions, which isn't necessarily bad. Tell your primary doctor the options you're considering and ask for help in determining the risks and benefits of each. "I try to take it from the patient's perspective and ask, 'If you had a preference and the outcomes were similar, what would you like to do?'" says Wherry. "Ultimately, you're the one who has to make this decision."

If there's major disagreement, seek a tiebreaker. Some health insurance companies will pay for a third specialist, Inlander says.

6. Make hurried doctors listen. You'll likely encounter several doctors of different skills and temperaments during this journey. Remember that some of the best physicians are the worst communicators; prescription pads never talk back. To make her doctor listen, Rodgers practiced this line: "I need to say something, and if you promise to listen without interrupting, I promise to speak for 90 seconds or less." It's a surefire way to get silence. It sounds far more reasonable than "just two minutes"—which doctors hear as patient-speak for "a half-hour or so." And, if you're well-prepared, 90 seconds is enough time to say everything you need to say (the "Gettysburg Address" took scarcely longer than that).

7. Get educated, not distraught. Finding health news and research about your condition on the Internet can be helpful, but it can also be a source of misinformation and needless worry. To ensure you're getting reliable information, stick with websites backed by known organizations. A prominent one is MedlinePlus ([medlineplus.gov](http://medlineplus.gov)), a site jointly provided by the U.S. National Library of Medicine and the National Institutes of Health. Also, the site at [healthfinder.gov](http://healthfinder.gov) has links to more than 1,800 health-related organizations.

Offline, some hospitals and university medical centers offer well-stocked medical libraries, with librarians and research assistants to help patients wade through them. For example, the Stanford University Medical Center's Health Library offers free research help to anyone seeking information on an illness or treatment. "We walk through every patient's case individually and provide scientifically based medical information to help them make informed decisions about their health care," says the director of special patient services, Barbara Ralston. To reach the library, call 800-295-5177 or visit [healthlibrary.stanford.edu](http://healthlibrary.stanford.edu).

Don't hand your doctor a thick sheaf of medical journal articles and expect him or her to read them on the spot. Instead, Inlander suggests, use your research to create a list of half a dozen "talking points," and offer your doctor copies of your research.

8. Choose your hospital wisely. The closest hospital may be convenient, but it's probably a poor choice unless its staff has a great deal of experience in treating patients in your situation. You can get a

quick read on this by checking [www.healthgrades.com](http://www.healthgrades.com), and by calling the hospital and asking the medical director how often its doctors treat your condition. If you find that the closest qualified hospital is 500 miles away, ask your doctor if he can consult with the specialists there.

9. After checking in, shake some hands. "When you get into your hospital room, the first thing you should do is call and ask the hospital's patient representative to come up so you can introduce yourself," Inlander says. "If you encounter problems, that person is responsible for making it right." (Ask for the patient representative's number when you check in, or ask a nurse.) Your friendliness will pay off if you have a problem; the advocate knows how to intervene if the night staff keeps waking you up to take your sleeping pill, for instance.

10. Chat up the nurses. It could yield more than extra pillows. "They have terrific insider information," says Dr. Hurst. Not only can they make your stay more comfortable, they can give you important treatment advice, too. You may need to listen for code words; a nurse could lose her job for telling you she wouldn't let your surgeon cut her hair. But if you hear a hint that she thinks you'd be better off with another doctor, take it seriously.

11. Stay sane. The emotional stress of battling a serious illness can take a large toll on your mental health—and the stability of your relationships. Joining a support group and venting to others who have been in your shoes can help; just make sure they're an optimistic bunch. "You can learn from other people who have gone through this situation," says Inlander, "but avoid groups that don't give you positive vibes."

12. Be blissfully self-indulgent. When you're recuperating, forget about being the "perfect patient"—cheerful, brave, and attuned to everyone else's needs. Take all the slack that friends and family readily give you during this furlough, and don't feel guilty. Karma will come around. "The good news, if you can call it that, is that everything you go through will help you be part of someone else's support system six months or a year from now," says Pesmen, who—knock on wood—has been cancer-free for two years. "It's a small bonus at the end of a long, hard ride."

*Elizabeth Austin is an award-winning health writer in Chicago.*

## CANCER MORTALITY CONTINUES TO FALL

(continued from page 1)

to decline in 1994, the investigators state. Although men continued to experience a slight fall in death rates throughout the 1990s, women's rates essentially stabilized between 1998 and 2000.

Mortality due to lung cancer continues to drop among black and white men, while the rate of increase in death rates has slowed among women, the findings indicate. Death rates for cancer of the breast, prostate, and colon all continue to fall.

In a related editorial, Dr. M. J. Quinn, from the National Cancer Intelligence Centre in London, comments that "a principal strength of the report is that it provides a wealth of information on the cancer trends in terms of both incidence and mortality."

"The establishment in the US of state cancer registries, in addition to the high quality Surveillance, Epidemiology, and End Result (SEER) registries, is a major step forward in cancer control," Dr. Quinn adds.

## EARLY DETECTION REDUCES PROSTATE CANCER DEATHS

New research shows earlier detection and wide use of hormone treatment have driven down prostate cancer's death rates.

A British researcher said death rates dropped by one-third in North America and by 20 percent in Europe since 1990 among men aged 65 to 74.

Previous studies have demonstrated hormone treatment delays the progression of prostate cancer and makes patients feel better. The new study offers evidence that the approach can save lives.

Prostate cancer is most often driven by the male sex hormone testosterone. Therapy blunts the ability of the hormone to stimulate cancer cells.

The findings were presented September 22 at a European conference on cancer.

## Make YOUR Best Treatment Choice for Early Prostate Cancer

Rachel Snyder - CancerSource

"In the late 80s, we found it was men with prostate cancer who wanted the least involvement in making their treatment decision—" says Lesley Degner, RN, PhD, "how things have changed!"

Today most men newly diagnosed with early stage (localized) prostate cancer—cancer that has not spread outside of the prostate gland—will not be content with saying, "Yes doctor, whatever you think is best." The number of treatment choices has gone up, and the side effects can change a man's life. This will cause many men to get more involved and to seek more information in order to make the "best choice," as described by Donna Berry, RN, AOCN, PhD.

In interviews with CancerSource, Degner and Berry provided treatment decision-making advice for men with early stage prostate cancer. They each have more than 25 years of experience studying decision-making and the human response to cancer, and new research recently published.<sup>1,2</sup> Read what they have to say for help in making the best treatment choice for you.

### The Diagnosis

If a man has some of the symptoms of prostate cancer, a doctor or nurse will first ask questions about these symptoms. A physical exam and other tests will be done. If any of these test results suggest that cancer may be present, the doctor will order a biopsy of the prostate. A biopsy is the only sure way of knowing whether a problem is because of cancer.

It takes about a week for the biopsy results to come back. "Physicians have their own preferences and styles," says Berry. "Men should ask their physician before the biopsy how they will hear about the results, for example, 'Will you call me or will you let me know at my next appointment?'"

Men should start learning about

treatment options soon after their diagnosis. Many men find themselves shocked, "I have cancer?!" This can make it hard to take in all of the information. Many people feel like they need to make a treatment decision quickly so the cancer doesn't spread. "Men shouldn't feel rushed to make a treatment decision even if they or their family are feeling anxious about it," says Degner. "A lot of people, when they're diagnosed with cancer, think it's growing like a mushroom. While there are some tumors that are extremely aggressive and very rapidly growing, the majority of prostate cancer tumors have been there for a long time, it was just that they were undetectable."

If you can tolerate waiting and the doctor says it is ok (the tumor is not growing fast), try to slow the treatment decision-making pace down. "Think very carefully about what you're doing and look at all of the options," says Degner.

"With prostate cancer it's never a bad idea to get a second opinion, it's a good idea!" says Berry. "The treatments for prostate cancer are very diverse, so many men feel comfortable when they talk to different specialist." A man should consider a second opinion as soon as they hear the biopsy results.

### Your Treatment Information and Discussion

Before hearing about the different treatment options, the man should tell the doctor about himself. "What happens too often is we load the person up with information and we don't listen," says Berry. "The conversation should focus on what the doctor needs to know about the man so decisions can be framed around who the man is and how the treatment fits into his life."

Both Degner's and Berry's new studies showed how personalizing the treatment discussion and information could help a man with his decision. Degner's study<sup>1</sup> looked at 74 couples in which a partner was newly diagnosed with early stage prostate cancer. In counseling sessions, these men and their partners talked about what was most important to them at the time of diagnosis. For example, for some men sexuality after treatment was the most

important to them. So, these men were given information about treatment based on how it would affect their sexuality. After receiving individualized information, four months after diagnosis most men reported that they took on a more active role in making the decision and their partners took on less of a role than they thought they would, and everyone involved had lower levels of stress.

Berry's study<sup>2</sup> looked at 44 men who were within 6 months of a diagnosis of early stage (localized) prostate cancer. The study was to see how men came to "making the best choice" for treatment. The researchers concluded that men make "the best choice for me" based on the medical information they received from all sources (the first doctor, second opinions, Internet, friends, etc.), plus personal factors (their job, past experiences with cancer, etc.). "The health care team has to customize the education they give men based on who they are and what they do," says Berry, "it's not enough to just provide medical information."

You may have to start the conversation about yourself, don't depend on your doctor to do so. "At a minimum men should be talking about what they do for a living, for recreation, who they know that's had cancer and what are the stories they've heard about men with prostate cancer or other people who have had cancer," says Berry. "Men can make a decision based on misinformation if they haven't talked to their doctor about what they've heard and what their priorities are."

Berry recommends that you lead your doctor towards this discussion by saying, "Well, before I hear about the treatment options and outcomes, I would like to tell you more about myself because it has a lot to do with my decision." For example, "I have a job where I walk a lot in my work. It's really important that you know that I can't get to a bathroom on the job, and I can't afford to take too much time off after surgery." Knowing this information, when the doctor talks about incontinence (unable to control urine) he can personalize the information. Rather than saying, "Your chances of incontinence are 15 percent," he can say, "Your chances of incontinence are 15 percent, and if you had surgery you may have to be

prepared to take six months off of work to resolve this side effect."

### *The Choices*

"Since there is no one best treatment for localized prostate cancer, most men are given the choice in treatment," says Berry, "the doctor and the man must work together to decide." Here is basic treatment information and questions that will help you successfully work with your health care team.

Common treatment options for early stage (localized) prostate cancer:

- **Surgery (called prostatectomy).** Surgical removal of the prostate and any remaining tumor.
- **Radiation Therapy.** X-rays used to kill cancer cells. External beam radiation is given outside of the body. Brachetherapy is done inside the body by placing radiation seeds into the prostate.
- **Watchful Waiting.** Monitoring or checking cancer that is growing slowly and will not do any harm for a long time, if ever.
- **Hormonal Therapy.** Lowers or blocks the male hormone, testosterone, to slow the growth of prostate cancer. This can be done by removal of the testicles, by giving an injection, or taking a pill.
- **Cryosurgery.** Kills cancer cells by freezing the prostate gland.

Most men are given the major treatment options of surgery and radiation, and they are usually told about watchful waiting. Whether the other options, such as cryosurgery or hormonal therapy, are discussed depends on the doctor. "It's hard to imagine that someone who has spent 10 to 20 years learning to do surgery would say that surgery is not a good option," says Berry. It is good to talk to doctors from various specialties and try to gather more information.

"In our research we have found that thousands and thousands of men, even if they're not able to say it, want to know their chances of a cure and how far the disease has spread," says Degner. "Write down your top questions before your discussion, and don't leave without having them answered. If you can't say them, give the doctor the piece of paper."

Men should ask about the doctor's record. For example, how much experience does the doctor have doing the treatment? Do they perform two or 100 a year? This will be a bigger issue in a small town or more rural setting. Men should also hear what the doctor's outcomes are. For example, what percent of the men cannot control their urine after the surgery and what percent are able to be totally dry. "Physicians will often quote the literature," says Berry, "but you don't want a quotation of an unknown expert, you want to base your decision on the record of the physician whose office you're sitting in."

Men should ask about the treatment scheduling. How often do they have treatment, how much time does it take, how much follow-up will it require? They should ask who will work with them on making the treatment decision and after it is made. "These questions are important just so the man knows what the routine is going to be," says Berry. "It's not just the short term stuff that you have to think about," says Degner, "make sure you also ask about the long term side effects." For example, with prostate cancer, the most common are erectile dysfunction (cannot get a penile erection) and urinary incontinence.

"Often times you're just focused on getting through the treatment, which is important," says Degner. "But, most people go on and survive their cancer and live to die of something else. You don't want to be living with the serious side effects of your cancer treatment for the rest of your life. But if you have to, it would be nice to know about it before you're treated, so you can at least make the choice."

### *References*

1. Davison BJ, Goldenberg SL, Gleave ME, Degner LF. Provision of Individualized Information to Men and Their Partners to Facilitate Treatment Decision-Making in Prostate Cancer. *Oncology Nursing Forum*, 2003 JanFeb;30(1):10714.
2. Berry DL, Ellis WJ, Woods NF, Schwien C, Mullen KH, Yang C. (2003). Treatment Decision Making by Men with Localized Prostate Cancer: The Influence of Personal Factors. *Urologic Oncology*, 2003, MarApr;21(2):93100.

### **Questions to ask about prostate cancer treatments**

#### **If you are having treatment**

- What are my treatment choices?
- What are the expected benefits of each kind of treatment?
- What are the risks of each treatment?
- What are the side effects of each treatment?
- Are there new treatments or clinical trials that I should consider?
- What are my chances of being cured?
- How will we know if this is working?
- How will each treatment affect my daily life?
- What are the chances of the tumor coming back again?

#### **Surgery**

##### **If considering surgery**

- What kinds of surgery can I consider? Which operation do you recommend for me?
- Will I need radiation after surgery?
- How will I feel after surgery?
- Where will the scars be? What will they look like?
- Will I have to do special exercises after surgery?
- When can I get back to my normal activities?

#### **Radiotherapy**

##### **If you are having radiotherapy**

- What is the goal of this treatment?
- How will the radiation be given?
- How many treatments will I get? Over what period of time?
- When will the treatment begin? When will it end?
- How will I feel during radiation therapy?
- What can I do to take care of myself during therapy?

#### **Hormonal Therapy**

##### **If you are having hormonal therapy**

- Why do I need this treatment?
- What drugs will I be taking? How often? For how long? What will they do?
- What can I do about side effects?
- If I need hormonal treatment, which would be better for me, drugs or an operation?
- How long will I be on this



## DOES SELENIUM REDUCE THE RISK OF DEVELOPING PROSTATE CANCER?

By Kathleen A. Wildasin

Results of a recent experimental study offer new insights into how dietary supplementation with a trace mineral might reduce the risk of prostate cancer.

David J. Waters, DVM, PhD, Director of the Gerald P. Murphy Cancer Foundation and Professor of Comparative Oncology at Purdue University, is leading a research team in the investigation of how selenium, a nutrient essential to the functioning of several metabolically important enzymes, inhibits the development of prostate cancer.

"Using elderly beagles to mimic 65-year-old men, we evaluated the effect of selenium on prostate cells in an appropriate context . . . *in vivo* in an aging prostate gland," Waters said.

Although most information on the mechanisms of anticancer agents has been gleaned from studies using animal tumor models, studying prostate cancer in the laboratory has been hampered by the fact that only one non-human species, the dog, develops this cancer spontaneously and with appreciable frequency.

The research of Waters and colleagues complements the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a study initiated in 2001 by the National Cancer Institute to evaluate whether selenium and/or vitamin E decreases the incidence of human prostate cancer. The largest prostate cancer prevention study ever undertaken, SELECT will evaluate more than 32,000 men during a 12-year period. The Gerald P. Murphy Cancer Foundation, a not-for-profit cancer research organization in West Lafayette, IN and Seattle, WA, is one of more than 400 sites in North America enrolling men into the SELECT Trial.

"In this study supported by the Department of Defense Prostate Cancer Research Program, we found that 7 months of daily oral supplementation, using the same form and dose of selenium currently being used in SELECT, significantly reduced the accumulation of DNA damage within prostate cells," Waters said.

In the February 5, 2003 issue of the *Journal of the National Cancer Institute*, the group also reported that daily selenium

supplementation was accompanied by a two-fold increase in prostate cell apoptosis. Apoptosis, an orderly process of cell death, can remove damaged cells from the prostate, which may lower the risk of cancer.

"Although several previous studies have shown that selenium can induce apoptosis in the cell culture laboratory, our results represent the most convincing evidence to date that DNA damage and apoptosis are selenium-responsive events within the prostate," Waters said.

Does this study provide evidence that selenium supplementation can be used to effectively treat prostate cancer?

"In our experiments, we studied the effects of selenium on the aging prostate gland prior to the development of prostate cancer," Waters said. "One should always use caution before concluding that an intervention that is beneficial in a prevention setting will also be beneficial for treatment."

Several scientists, including Waters, are actively investigating the effect of selenium on cancer cells in the laboratory. "There is still a lot about selenium's effect on the prostate that remains unknown to us," Waters conceded.

The long-term research goal of Dr. Waters' comparative oncology team is to accelerate the development and application of effective cancer prevention and treatment strategies that will benefit both people and pet animals who are at high risk of developing cancer.

For more information regarding this article, contact Kathleen Wildasin at [kwildasin@insightbb.com](mailto:kwildasin@insightbb.com)

For more information regarding research on selenium and prostate cancer, visit the Murphy Foundation website ([www.gpmcf.org](http://www.gpmcf.org)), under the section "About Selenium."

### SOURCES:

- (1) Personal communication (telephone, e-mail) with Dr. David Waters (May 2003).
- (2) Waters DJ, Shen S, Cooley DM, et al. Effects of Dietary Selenium Supplementation on DNA Damage and Apoptosis in Canine Prostate. *J Natl Cancer Inst* 2003;95(3):237-241.
- (3) Jennifer Warner, Selenium May Fight Prostate Damage. *WebMD Medical News*, February 2003.
- (4) Jodi Knapik, Aultman Hospital Enrolling Men in Prostate Cancer Prevention Trial. Aultman News Press Release, accessed May 7, 2003.

## Us Too! AND OUTDOOR CHANNEL PARTNERSHIP

(continued from page 1)

effort to promote awareness, education, prevention and treatment of the disease that will be newly diagnosed in more than 220,000 men in the USA this year. To this end, the International cable network will draw upon its reach to more than 60 million homes in the United States and Latin America.

"Every sixteen minutes someone dies of prostate cancer in this country alone," said John Page, President and CEO of *Us Too! INTERNATIONAL*. "This simply does not have to be. There are more effective treatment options today than ever before, and death from Prostate Cancer can be practically 100% avoidable if men simply take responsibility for their health and get tested annually to detect the disease early."

"Our viewers are mostly male, and men of an age ideal for early awareness and education of prostate cancer prevention," said Amy Hendrickson, Senior Vice President of Affiliate Sales and Marketing for The Outdoor Channel. "We believe this is one of the most effective and meaningful ways we can fulfill our responsibility to help better the community that we serve."

## POSITIVE MULTICENTER CRYO RESULTS

(continued from page 2)

while 79 of 106 (75%) remained free from biochemical recurrence at 12 months. A total of 42 (78%) low risk patients (Gleason score 7 or less and PSA 10 or less) remained with a PSA of 0.4 ng/ml or less at 12 months of followup, compared to 37 (71%) high risk patients. All patients were discharged within 24 hours.

### CONCLUSIONS

After a followup of 1 year 3rd generation cryosurgery appears to be well tolerated and minimally invasive. The use of ultrathin needles through a brachytherapy template allows for a simple percutaneous procedure and a relatively short learning curve. A prospective multicenter trial is ongoing to determine the long-term efficacy of this technique.

**Prostate Cancer Risk and DNA Damage: Translational Significance  
of Selenium Supplementation in a Canine Model**

Keynote Speaker: David J. Waters, DVM, PhD  
Professor of Comparative Oncology, Purdue University  
Director, Gerald P. Murphy Cancer Foundation

Daily supplementation with the essential trace mineral selenium significantly reduced prostate cancer risk in men in the Nutritional Prevention of Cancer Trial. However, the optimal intake of selenium for prostate cancer prevention is unknown. We are conducting randomized feeding trials in dogs to study the consequence of nutritionally adequate or supranutritional selenium status at concentrations that mimic the range of selenium intake of healthy men in the United States. By studying elderly dogs, the only non-human animal model of spontaneous prostate cancer, we are defining the dose-response relationship between dietary selenium and prostatic DNA damage. Our results have important implications for the design of human cancer prevention trials and for optimizing selenium supplementation as a practical cancer prevention strategy.

**International Conference on Antimutagenesis and Anticarcinogenesis, Pisa, ITALY,  
November 2003**

## **RELATIONSHIP BETWEEN SELENIUM STATUS AND THE EXTENT OF GENOTOXIC STRESS WITHIN THE AGING PROSTATE**

David J. Waters<sup>1,5</sup>, Shuren Shen<sup>1,5</sup>, Dawn M. Cooley<sup>1,5</sup>, David G. Bostwick<sup>3</sup>, Junqi Qian<sup>3</sup>, Lawrence T. Glickman<sup>2</sup>, J. Steven Morris<sup>4</sup>

Departments of Veterinary Clinical Sciences<sup>1</sup> and Veterinary Pathobiology<sup>2</sup> (ltg@purdue.edu); Bostwick Laboratories<sup>3</sup> (bostwick@bostwicklaboratories.com, jqian@bostwicklaboratories.com); University of Missouri-Columbia Research Reactor Center<sup>4</sup> (morrisj@missouri.edu); Gerald P. Murphy Cancer Foundation<sup>5</sup> (dwaters@gpmcf.org, sshen@gpmcf.org, dmc@gpmcf.org).

Analysis of toenails from men in the Health Professionals Follow-up Study showed an inverse association between selenium status and risk for advanced prostate cancer, with no substantial reduction in prostate cancer risk in men with toenail selenium concentration exceeding 0.85 ppm. In a previous study, we found that daily supplementation with selenomethionine or high selenium yeast significantly reduced DNA damage within the prostate of elderly dogs of a comparable physiologic age to men enrolled in the Selenium and Vitamin E Prostate Cancer Prevention Trial (SELECT). The objective of this study was to determine if toenail selenium concentration provides a readily accessible surrogate biomarker predictive of the extent of genotoxic damage within the prostate. We studied 49 (8.5 – 10.5 year old) sexually intact male, retired breeder dogs that were randomly assigned to either a control group or to receive daily supplementation with selenomethionine or high selenium yeast at 3 or 6 µg/kg body weight. After 7 months, toenail and prostate tissue specimens were collected immediately after euthanasia and analyzed for total selenium concentration using neutron activation analysis. Dogs from control and selenium treated groups were combined and subdivided into quartiles based on their toenail selenium concentration to evaluate the relationship between toenail selenium level and extent of DNA damage within the prostate as measured by alkaline comet assay. Dogs with the lowest toenail selenium concentration had the highest extent of genotoxic damage within the prostate (ANOVA,  $p < 0.0001$ ). The relationship between the percentage of cells with extensively damaged DNA and toenail selenium concentration was non-linear and U-shaped. In dogs that had toenail concentrations in the two lowest quartiles, there was a significant inverse correlation between DNA damage within the prostate and selenium status ( $r = -0.78$ ,  $p < 0.0001$ ). There was no additional decrease in DNA damage within the prostate of dogs that had toenail selenium concentration in the two highest quartiles (i.e.  $> 0.75$  ppm). In fact, the extent of DNA damage increased with increasing concentrations of toenail selenium in dogs in the two highest quartiles ( $r = 0.44$ ,  $p = 0.03$ ). A strong positive correlation was found between intraprostatic and toenail concentrations of selenium ( $r = 0.72$ ,  $p < 0.0001$ ). These findings support the hypothesis that toenails are a readily accessible surrogate tissue for monitoring the effects of dietary selenium supplementation on total selenium levels and carcinogenic events within the aging prostate. The possibility of a threshold for the prostate cancer protective effects of selenium that can be assayed non-invasively, warrants further investigation.

**Is the Anti-Trophic Effect of the 5 $\alpha$ -Reductase Inhibitor Finasteride on the Aging Prostate Influenced by Selenium Status?**

Dawn M. Cooley<sup>5</sup>, Shuren Shen<sup>5</sup>, Carol Oteham<sup>1</sup>, Deborah Schlittler<sup>1</sup>, Lawrence T. Glickman<sup>1</sup>, David G. Bostwick<sup>2</sup>, J. Steven Morris<sup>3</sup>, Gerald F. Combs Jr<sup>4</sup>, David J. Waters<sup>1</sup>

Purdue University<sup>1</sup>, West Lafayette, IN; Bostwick Laboratories<sup>2</sup>, Richmond, VA; University of Missouri-Columbia Research Reactor Center<sup>3</sup>, Columbia, MO, Cornell University<sup>4</sup>, Ithaca, NY; Gerald P. Murphy Cancer Foundation<sup>5</sup>, Seattle, WA.

In previous work, we showed that daily selenium supplementation reduced DNA damage and increased epithelial cell apoptosis within the aged dog prostate. These results add to a growing body of evidence that trace minerals, such as selenium or zinc, play an important role in genomic protection and growth control within the prostate. Daily treatment with finasteride, a 5 $\alpha$ -reductase inhibitor that exerts potent anti-trophic effects on the prostate, is currently under extensive evaluation as an approach to prostate cancer prevention. The purpose of this study was to test the hypothesis that selenium status significantly influences the prostate's response to daily treatment with finasteride. We studied elderly (8.5-10.5 year-old) sexually intact male beagle dogs with nutritionally adequate selenium status. Fifty-seven dogs were randomly assigned to: a control group (n=13 dogs); or to receive daily supplementation with finasteride (0.5 mg/kg) (n=9 dogs); supranutritional dietary selenium (3  $\mu$ g/kg high selenium yeast, SelenoExcell, Cypress Systems, Fresno, CA) (n=15 dogs); or high selenium yeast plus finasteride (n=10 dogs). As the first step in analyzing our experimental results, we focused on the effects of treatment on prostate volume. For each dog, prostate size in 3 dimensions was measured with calipers prior to treatment and after 6 to 7 months treatment. Prostate weight was calculated using the formula: weight (g) = volume (cm<sup>3</sup>) x 0.602 + 1.16. The anti-trophic effect of finasteride on the prostate was assessed by calculating the percent change in prostate volume over the treatment period. Actual prostate weight recorded at the end of the study was strongly correlated with prostate weight calculated from prostate volume (r = 0.963; p < 0.0001), validating prostate volume as a robust and reliable index of prostate growth. Dogs in the control group had a median change in prostate volume of +15% over the treatment period. Similarly, dogs receiving supranutritional selenium supplementation had a 16% median increase in prostate volume. In contrast, finasteride-treated dogs had a 42% median reduction in prostate volume after 6 months of treatment (p<0.0001 vs. control group). Finasteride-treated dogs that received supranutritional selenium had a 38% median reduction in prostate volume, which did not differ from dogs treated with finasteride alone (p=0.52). These preliminary data suggest that selenium status does not significantly influence the anti-trophic effects of finasteride on the aging prostate. The dog model enables us to study *in vivo* how differences in selenium status (i.e., nutritionally adequate versus supranutritional) influence prostate cell response to other potential cancer preventive agents. Further analysis of these dogs will determine to what extent the combination of selenium and finasteride affect biomarkers of growth regulation and carcinogenesis within the aging prostate.